TMF-13854840  CONFIDENTIAL   
GlaxoSmithKline group of companies   201771  
 1 
 TITLE PAGE  
Protocol Title: A repeat dose, open label, two period, randomized, cross over study to 
compare the effect of daprodustat to recombinant, human erythropoietin (rhEPO) on oral 
iron absorption in adult participants with anemia associated with chronic kidney disease 
who are not on dialysis  
Protocol Number : 201771  /Amendment 3 
Short Title : Anemia Studies in CKD: Erythropoiesis via a Novel PHI Daprodustat – Iron 
(ASCEND -Fe)  
Compound 
Number:  GSK1278863  
Study Phase 2b  
Sponsor Name and Legal Registered Address:  
GlaxoSmithKline Research & Development Limited  
980 Great West Road  
Brentford  
Middlesex, TW8 9GS  
UK 
Medical Monitor Name and Contact Information  can be found in the Study Reference 
Manual (SRM)  
Regulatory Agency Identifying Number(s):  IND Number: 101,291  
Approval Date: 14-JUL -2021  
 
 
 
 
 
 
 
 
Copyright 2021  the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited.  
TMF-13854840  CONFIDENTIAL   
  201771  
 2 
 SPONSOR SIGNATORY:  
Protocol Title: A repeat dose, open label, two period, randomized, cross over study to 
compare the effect of daprodustat to recombinant, human erythropoietin (rhEPO) on oral 
iron absorption in adult participants with anemia associated with chronic kidney disease 
who are not on dialysis  
Protocol Number : 201771 /Amendment 3  
Compound Number 
or Name:  GSK1278863   
 
 
 
 
Alexander R. Cobitz, MD, PhD  
Senior Director  
Daprodustat Clinical Development Lead  
Specialty (Clinical Sciences)  
GlaxoSmithKline  
 
The signed page is a separate document.  
 
 
 
  Date  
TMF-13854840  CONFIDENTIAL   
  201771  
 3 
 PROTOCOL AMENDMENT SUMMARY OF CHANGES T ABLE  
DOCUMENT HISTORY  
Document  Date  Document Identifier  
Amendment 3  14-Jul-2021  TMF-13854840  
Amendment 2  13-Aug-2019  2016N298210_02  
Amendment 1  30-Nov-2017  2016N298210_01  
Original Protocol  12-May-2017  2016N298210_00  
 
Amendment 3: 14-JUL -2021   
Overall  Rationale for the Amendment :  
Amendment 3  was implemented to facilitate enrolment and the maintenance  of 
participants once randomized in the study and to correct noted typographical errors.   
Section # and 
Name  Description of Change  Brief Rationale  
5.1 O verall 
Design  Table 1 : number to be 
enrolled in each possible 
sequence corrected from 6 
to 3 
 
Day of crossover changed 
from Day 28 to Day 29  
 To correct discrepancy  
5.4 Scientific 
Rational e for 
Study Design  Bullet 9: deleted hepcidin  
level assessment  as 
eligibility criterion  Exclusion criterion related to hepcidin 
was removed after observing 
variability in the range of hepcidin 
results and the lack of standardization 
of hepcidin assays making it difficult 
to establish a cut -off value for this  
study po pulation.  6.1 Exclusion 
Criteria  Deletion of Exclusion 
Criteria #12 Hepcidin >150  
ng/ml  
9.4.1 Entry 
Criteria (Table 
4) Hepcidin was removed as 
an entry criteria assessment  
8.2.1.2 Iron 
Stopping 
Criteria  Amended to allow the 
Investigator to use his 
clinical judgement and 
removed TSAT and ferritin 
values as discontinuation 
criteria.   The intent of the iron stopping criteria 
is to ensure parti cipants remain on the 
same dose of oral iron supplement 
throughou t the study.  Therefore, the 
stopping criteria was amended to 
allow the Investigator to use his 
clinical judgement to determine if a 
TMF-13854840  CONFIDENTIAL   
  201771  
 4 
 Section # and 
Name  Description of Change  Brief Rationale  
participant’s iron supplement required 
adjustment.  
5.4 Scientific 
Rational e for 
Study Design  Removed mention of 
absolute change in 
Hemoglobin  to define the 
evaluable population  Hemoglobin variability is managed 
through the hgb stopping criteria  10.3.1.3 
Evaluable 
Population  Deleted  the criterion of  
absolute changes from 
baseline (Day 1 pre dose) in 
haemoglobin ≤0.75 g/dL 
from the evaluable 
population definition  
12.3 Appendix 
3 Risk 
Assessment  Drug Interaction 
information updated   Modified to maintain c onsistency 
with current Risk Assessment  
12.7 Appendix 
7 Contraceptive 
Guidance and 
Collection of 
Pregnancy 
Information  Urine pregnancy testing kit 
sensitivity  corrected from 2 
mIU/mL to 25 mIU/mL  To correct typographical error.  
 
 
TMF-13854840  CONFIDENTIAL   
  201771  
 5 
 TABLE OF CONTENTS  
PAGE  
PROTOCOL AMENDMENT S UMMARY OF CHANGES TA BLE ................................ ..... 3 
1. SYNOPSIS  ................................ ................................ ................................ ...............  8 
2. SCHEDULE OF ACTIVITI ES (SOA)  ................................ ................................ ....... 10 
3. INTRODUCTION  ................................ ................................ ................................ .... 12 
3.1. Study Rationale  ................................ ................................ ..........................  12 
3.2. Backgro und ................................ ................................ ................................  13 
3.3. Benefit/Risk Assessment  ................................ ................................ ............  13 
3.3.1.  Risk Assessment  ................................ ................................ .........  13 
3.3.2.  Benefit Assessment  ................................ ................................ ..... 14 
3.3.3.  Overall Benefit:Risk Conclusion  ................................ ...................  14 
4. OBJECTIVES AND ENDPO INTS  ................................ ................................ ...........  14 
5. STUDY DESIGN  ................................ ................................ ................................ .... 15 
5.1. Overall Desig n ................................ ................................ ............................  15 
5.2. Number of Participants  ................................ ................................ ...............  16 
5.3. Participant and Study Completion  ................................ ...............................  16 
5.4. Scientific Rationale for Study Design  ................................ ..........................  16 
5.5. Dose Justification  ................................ ................................ ........................  18 
6. STUDY POPULATION  ................................ ................................ ...........................  18 
6.1. Inclusion Criteria  ................................ ................................ .........................  18 
6.2. Exclu sion Criteria  ................................ ................................ ........................  19 
6.2.1.  Hgb Stability Criteria  ................................ ................................ .... 21 
6.3. Lifestyle Restrictions  ................................ ................................ ...................  22 
6.4. Screen Failures ................................ ................................ ...........................  22 
7. TREATMENTS  ................................ ................................ ................................ ....... 23 
7.1. Treatments Admi nistered  ................................ ................................ ............  23 
7.1.1.  Daprodustat Dosing Information  ................................ ..................  24 
7.1.2.  rhEPO Dosing Information  ................................ ...........................  24 
7.1.3.  57Fe Dosing Information  ................................ ...............................  24 
7.1.4.  58Fe Dosing Information  ................................ ...............................  24 
7.2. Dose Modification  ................................ ................................ .......................  25 
7.3. Metho d of Treatment Assignment  ................................ ...............................  25 
7.4. Blinding  ................................ ................................ ................................ ....... 25 
7.5. Preparation/Handling/Storage/Accountability  ................................ ..............  25 
7.6. Treatment Compliance  ................................ ................................ ................  26 
7.7. Concomitant Therapy ................................ ................................ ..................  26 
7.7.1.  Permitted Medications and Non -Drug Therapies  ..........................  26 
7.7.2.  Prohibited Medications and Non -Drug Therapies  .........................  27 
7.7.3.  Standard of Care  ................................ ................................ .........  27 
7.8. Treat ment after the End of the Study  ................................ ..........................  27 
8. DISCONTINUATION CRIT ERIA  ................................ ................................ .............  27 
8.1. Discontinuation of Study Treatment  ................................ ............................  27 
TMF-13854840  CONFIDENTIAL   
  201771  
 6 
 8.1.1.  Liver Chemistry Stopping Criteria  ................................ ................  27 
8.2. Withdrawal from the Study  ................................ ................................ ..........  28 
8.2.1.  Criteria for Permanent Discontinuation from Study 
Treatment and Early  Withdrawal  ................................ ..................  29 
8.2.1.1.  Hgb Stopping Criteria  ................................ .................  29 
8.2.1.2.  Iron Stopping Criteria  ................................ ..................  30 
8.3. Lost to Follow Up  ................................ ................................ ........................  30 
9. STUDY ASSESSMENTS AN D PROCEDURES  ................................ .....................  31 
9.1. Efficacy Assessments  ................................ ................................ .................  31 
9.2. Adverse Events ................................ ................................ ...........................  31 
9.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  ................................ ................................ ...................  32 
9.2.2.  Method of Detecting AEs and SAEs  ................................ .............  32 
9.2.3.  Follow -up of AEs and SAEs  ................................ .........................  32 
9.2.4.  Adverse Events of Special Interest (AESI)  ................................ ... 32 
9.2.5.  Regulatory Reporting Requirements for SAEs  .............................  33 
9.2.6.  Cardiovascular and Death Events  ................................ ................  33 
9.2.7.  Possible Suicidality Related Adverse Events  ...............................  34 
9.2.8.  Pregnancy  ................................ ................................ ...................  34 
9.3. Treatment of Overdose  ................................ ................................ ...............  34 
9.4. Safety Assessments  ................................ ................................ ...................  35 
9.4.1.  Entry Criteria  ................................ ................................ ................  35 
9.4.2.  Physi cal Examinations  ................................ ................................ . 35 
9.4.3.  Vital Signs  ................................ ................................ ....................  35 
9.4.4.  Electrocardiograms  ................................ ................................ ...... 36 
9.4.5.  Clinical Laboratory Assessments  ................................ .................  36 
9.4.6.  Liver Chemistry Monitoring  ................................ ..........................  36 
9.5. Pharmacokinetics  ................................ ................................ .......................  36 
9.6. Pharmacodynamics  ................................ ................................ ....................  37 
9.7. Genetics  ................................ ................................ ................................ ..... 37 
9.8. Biomarkers  ................................ ................................ ................................ . 37 
9.8.1.  Fractional oral iron absorption  ................................ ......................  37 
9.8.2.  Iron status markers  ................................ ................................ ...... 37 
9.8.3.  Indices of erythropoiesis  ................................ ..............................  37 
9.9. Health Economics OR Medical Resource Utilization and Health 
Economics  ................................ ................................ ................................ .. 37 
10. STATISTICAL CONSIDER ATIONS  ................................ ................................ ........  38 
10.1.  Hypotheses  ................................ ................................ ................................ . 38 
10.2.  Sample Siz e Determination  ................................ ................................ ........  38 
10.2.1.  Sample Size Sensitivity  ................................ ................................  38 
10.2.2.  Sample Size Re -estimation  ................................ ..........................  38 
10.3.  Data Analysis Considerations  ................................ ................................ ..... 39 
10.3.1.  Analysis Populations  ................................ ................................ .... 39 
10.3.1.1.  Screened Population:  ................................ .................  39 
10.3.1.2.  Safety Population:  ................................ ......................  39 
10.3.1.3.  Evaluable Population:  ................................ .................  39 
10.3.1.4.  Modified Intent to Treat (mITT) Population:  ................  39 
10.3.2.  Interim Analyses  ................................ ................................ ..........  39 
10.4.  Key Elements of Analysis Plan  ................................ ................................ ... 39 
10.4.1.  Primary Analysis  ................................ ................................ ..........  39 
TMF-13854840  CONFIDENTIAL   
  201771  
 7 
 10.4.2.  Secondary Analysis  ................................ ................................ ..... 40 
11. REFERENCES  ................................ ................................ ................................ ....... 41 
12. APPENDICES  ................................ ................................ ................................ ........  43 
12.1.  Appendix 1: Abbreviations and Trademarks  ................................ ................  43 
12.2.  Appendix 2: Liver Safety Required Actions and Follow up 
Assessments  ................................ ................................ ..............................  46 
12.3.  Appendix 3: Risk Assessment  ................................ ................................ ..... 49 
12.4.  Appendix 4: Clinical Laboratory Assessments  ................................ ............  60 
12.5.  Appendix 5: Study Governance Considerations  ................................ ..........  62 
12.6.  Appendix 6: Adverse Events: Definitions and Procedures for  
Recording, Evaluating, Follow -up, and Reporting  ................................ ....... 66 
12.7.  Appendix 7: Contraceptive Guidance and Collection of Pregnancy 
Information  ................................ ................................ ................................ .. 71 
12.8.  Appendix 8: Genetics  ................................ ................................ ..................  74 
12.9.  Appendix 9: Protocol Amendment History  ................................ ...................  75 
 
TMF-13854840  CONFIDENTIAL   
  201771  
 8 
 1. SYNOPSIS  
Protocol Title:  A repeat dose, open label, two period, randomized, cross over  study to 
compare the effect of daprodustat to recombinant, human erythropoietin (rhEPO) on oral 
iron absorption in adult participants with anemia associated with chronic kidney disease 
who are not on dialysis  
Short Title:   Anemia Studies in CKD: Erythropo iesis via a Novel PHI Daprodustat – 
Iron (ASCEND -Fe)  
Rationale:   Several proteins involved in iron absorption/metabolism are known to be HIF 
target genes.  In this regard, daprodustat is equipotent against 3 human PHD enzymes 
(PHD1, PHD2 & PHD3) thereby s tabilizing both HIF1 α and HIF2 α.  Increased iron 
absorption correlates with increased expression in enterocytes and proerythroblasts of 
divalent metal -iron transporter 1 (DMT1), duodenal cytochrome b561 (DcytB) and 
ferroportin (FPN) mRNA.  HIF -2α is reported to up -regulate the expression of these 
genes by direct binding to consensus hypoxia response elements (HRE).  Thus, there is 
the potential that daprodustat administration, by virtue of increasing HIF levels, can 
increase oral iron absorption a nd incorporation into Hgb.  Therefore, the purpose of this 
study is to compare the effect of daprodustat to rhEPO (i.e., epoetin alfa or darbepoetin 
alfa) on non -heme oral iron absorption using stable isotopic iron (57Fe & 58Fe) by 
measuring incorporation of iron in erythrocytes.  
Objectives and Endpoints : 
Objectives  Endpoints  
Primary  
• Compare the efficacy of daprodustat to 
rhEPO (i.e., epoetin alfa or darbepoetin 
alfa) on iron absorption  • Difference in fractional oral iron 
absorption (%) between daprodustat  and 
rhEPO  
Secondary  
• Characterize the effect of daprodustat or 
rhEPO on markers of iron status  • Change from baseline (Day 1) at 14 and 
28 days following treatment with 
daprodustat or rhEPO in serum iron, 
transferrin, transferrin saturation, soluble 
transferrin receptor, ferritin, hepcidin and 
erythroferrone  
• Characterize the effect of daprodustat or 
rhEPO on indices of erythropoiesis  • Change from baseline (Day 1) at 14 and 
28 days following treatment with 
daprodustat  or rhEPO in Hgb, hematocrit, 
red blood cell number, mean corpuscular 
volume, reticulocyte Hgb and 
reticulocyte number  
TMF-13854840  CONFIDENTIAL   
  201771  
 9 
 Objectives  Endpoints  
Safety  
• Assess safety and tolerability  • Incidence and severity of adverse events 
and serious adverse events  
• Reasons for discontinuation of study 
medication  
• Vital signs assessments  
 
Overall Design:   This study will be a randomized, repeat dose, open label, two period 
cross -over study in adult, male and female participants with anemia associated with 
chronic kidney disease who are not on di alysis currently treated with stable doses (≤ 50% 
change in 4 -weekly dose) for at least 8 weeks prior to and including the screening period, 
of rhEPO (i.e., epoetin alfa or darbepoetin alfa) . 
Number of Participant s:  Sufficient participants will be enrolle d such that at least 12 
participants comprise the Evaluable Population.  
Treatment Groups and Duration:  
 
• There will be a 4 -week screening period in order to confirm that participants have 
stable Hgb levels and to assess entry criteria  
• A 28 -day Treatment Period 1 for incorporation of iron into erythrocytes while on 
randomized study treatment  
• A 28 -day Treatment Period 2 for a second incorporation of iron into erythrocytes 
while on randomized study treatment  
• A follow -up visit 14 ± 3 days after completing tre atment.  
 

TMF-13854840  CONFIDENTIAL   
  201771  
 10 
 2. SCHEDULE OF ACTIVITI ES (S OA) 
Procedure Screening1 Treatment Period2 Follow -up1 
Week -4 Week -2 Day 1  Day 15 Day 2 93 Day 4 3 Day 5 7 Day 70  
Informed Consent  X        
Entry Criteria  X4 X4 X4      
Physical, Medical History, Demography , 
Height  X5,9 X5,9 X5,9      
Weight  X  X X  X   
HemoCue Hgb  X X X X X X X  
eGFR  X        
Females: Urine Pregnancy Test6 X  X  X  X X 
Females: Estradiol & FSH7  X       
HIV screening  and Hepcidin  X        
Randomization    X      
Administration of isotopic iron     X  X   
Blood sampling for isotopic iron      X X X  
Crossover8     X    
ECG   X      X 
Vital sign s X  X  X  X X 
Clinical chemistry & hematology10 X       X 
Urinalysis10 X       X 
Liver chemistry monitoring11    X  X   
Folate & Vitamin B 12  X       
hsCRP   X       
Ferritin and TSAT    X       
Iron status markers12   X X X X X  
Indices of erythropoiesis13   X X X X X  
Blood draw for PGx    X      
AE and SAE Assessment14 X15 X15 X X X X X X 
Review Concomitant Medications  X X X X X X X X 
 
TMF-13854840  CONFIDENTIAL   
  201771  
 11 
 1 Allowable time window ± 3 days.  
2 Allowable time window ± 2 days.  
3 All assessments to be performed PRIOR  to crossing over.  
4 Criteria to be assessed can be found in  Section  9.4.1 . 
5 Complete physical examination, medical history & demography to be performed at Week -4, while a brief physical examination to be performed  at Week -2 and Day 1 . 
6 Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC.  
7 As detailed in Inclusion Criteria.  
8 Participants that had been administered daprodustat during treatment Period 1 will be switched to rhEPO , while those on rhEPO  will be switched to daprodustat.  Examples  on 
switching are provided  in the Study Reference Manual ( SRM ).  
9 Height is only collected at Week -4.   
10 Clinical laboratory assessment s guidance  can be found in Section 9.4.5  
11 Liver chemistry monitoring guidance can be found in Section  9.4.6 . 
12 Iron status markers include serum iron,  ferritin,  transferrin, transferrin saturation (TSAT), soluble transferrin receptor, hepcidin and erythroferrone  and are described in Section 9.8.2 . 
All samples for iron status markers to be taken pre dose.  
13 Indices of erythropoiesis include Hgb, hematocrit, red blood cell number, mean corpuscular volume, reticulocyte Hgb and reticulocyte number  and are described in Section 9.8.3 . 
14 Guidance on the timing and need for collection of AEs & SAEs are described in Section 9.2. 
15 SAEs assessed as related to study participation or a GSK product are collected at this visit.  See Section 9.2.1  for additional details.  
 
• The timing and number of planned study assessments, including  safety or biomarker  assessments may be altered during the course 
of the stud y based on newly available data  to ensure appropriate monitoring.   
• Any changes in the timing or addition of time points for any planned study assessments must be documented and approved by the  
relevant study team member and then archived in the sponsor and site study files but  will not constitute a protocol amendment.  
The IRB/IEC will be informed of any safety issues that require alteration of the safety monitoring  scheme or amendment of the 
ICF. 
 
TMF-13854840  CONFIDENTIAL   
  201771  
 12 
 3. INTRODUCTION  
Daprodustat (GSK1278863) is a small molecule, oral inhibiter of the hypoxia -inducible 
factor (HIF ) prolyl -4-hydroxylase (PHD) enzymes which may present several important 
advantages over recombinant, human erythropietin  (rhEPO ).  It is an oral medication and 
does not require cold -chain storage as do some rhEPOs , thus increasing ease of use for 
patients.  Moreover, data indicate that , similar to other HIF -PHD inhibitors,  daprodustat 
can effectively raise hemoglobin  (Hgb) concent rations with lower erythropoietin (EPO) 
levels than those observe d after administration of rhEPOs (Besarab , 201 5; Holdstock , 
2016 ).  Because of the increased cardiovascular (CV) risk associated with raising Hgb 
concentrations through  large increases in EPO levels ( Pfeffer , 2009) , daprodustat has the 
potential to treat patients  with less CV risk than rhEPOs .  Additional benefits include the 
potential to treat anemia without causing rhEPO -induced hypertension, to improve iron 
availability for erythropoiesis, and the potential to successfully treat rhEPO hypo -
responders  (Holdstock , 2016) . 
3.1. Study Rationale  
Sufficient iron availability is critical for normal erythropoiesis and all rhEPO labels carry 
guidance with regard to iron availability.  It is anticipated that the majority of patients 
with chronic kidney disease (CKD) will require supplemental iron durin g the course of 
rhEPO therapy.  However, poor compliance is seen with oral iron therapy due to 
gastrointestinal intolerance , while intravenous (IV) iron has an increased risk of infection 
and/or iron overload as well as an increased risk of anaphalaxis and  congestive heart 
failure.  Excess accumulation of iron in tissues with IV iron is clearly associated with 
increased morbidity and mortality with organ dysfunction primarily seen in the liver, 
heart, pancreas, joints and endocrine organs.  Further, most of  the morbidity and 
mortality due to iron overload disorders is the result of iron accumulation in the heart  
(Macdougall , 2016) .  Finally, administration of IV iron is associated with additional costs 
related to in -hospital administration and the need for patient monitoring.  
Several proteins involved in iron absorption/metabolism are known to be HIF target 
genes.  In this regard, daprodustat is equipotent agai nst 3 human PHD  enzymes (PHD1, 
PHD2 & PHD3) thereby stabilizing both HIF1 α and HIF2 α.  Increased iron absorption 
correlates with increased expression in enterocytes and proerythroblasts of divalent 
metal -iron transporter 1 (DMT1), duodenal cytochrome b561 (DcytB) and ferroportin 
(FPN) mRNA.  HIF -2α is reported to up -regulate the expression of these genes by direct 
binding to consensus hypoxia response elements (HRE)  (Koury , 2015) .  Thus, there is the 
potential that daprodustat administration, by virtue of increasing HIF levels, can increase 
oral iron absorption  and incorporation into Hgb .  Therefore, the purpose of this study is to 
compare the effect of daprodustat to rhEPO (i.e., epoetin alfa or darbepoetin alfa) on non -
heme oral iron absorption using stable isotopic iron (57Fe & 58Fe) by measuring 
incorporation of iron in erythrocytes.   The coordination of erythropoietin synthesis with 
iron metabolism by HIF is shown in Figure 1. 
TMF-13854840  CONFIDENTIAL   
  201771  
 13 
 Figure 1 HIF in erythropoietin synthesis and iron metabolism  
 
DcytB: Duodenal cytochrome b reductase 1; DMT1: Divalent metal transporter -1; FPN: Ferroportin; TF: 
Transferrin; EPO: Erythropoietin; GDF15: Growth Differentiation Factor 15 ( Koury , 201 5) 
3.2. Background  
HIF prolyl hydroxylase inhibitors (PHIs) are an emerging class of agents under 
investigation for the treatment of anemia associated with CKD.  These molecules 
stimulate erythropoies is through inhibition of HIF -prolyl hydroxylase domain enzymes 
(PHD1, PHD2, PHD3).  This activity results in the accumulation of HIFα transcription 
factors which leads to increased transcription of HIF -responsive genes, stimulating 
components of the natura l response to hypoxia.  During hypoxia, the PHD enzymes are 
inhibited, resulting in the accumulation of unhydroxylated HIFα subunits, which dimerize 
with HIFβ subunits to affect the transcription of HIF -responsive genes, including EPO 
and others involved i n increasing oxygen availability and utilization.  Other functions 
regulated by HIFs include iron metabolism and utilization, angiogenesis, extracellular 
matrix metabolism, apoptosis, energy and glucose metabolism, vascular ton e, cell 
adhesion, and motilit y (Haase , 2013) . 
3.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks of 
daprodustat  may be found in the Investigator’s Brochure  (IB) and supplements . 
3.3.1.  Risk Assessm ent 
The potential risks of clinical significance including adverse events ( AEs) of special 
interest ( AESI; Section 9.2.4 ), and the mitigation strategies for this protocol taking into 
account the results of completed clinical and nonclinical studies with daprodustat, are 
outlined in  Appendix 3. 

TMF-13854840  CONFIDENTIAL   
  201771  
 14 
 3.3.2.  Benefit Assessment  
In clinical trials of up to 24 weeks in duration, in participant s with anemia associated with 
CKD, daprodustat has been shown to increase Hgb to target ra nge.  Data from prior 
studies with daprodustat suggest that the increases in Hgb are achieved with EPO levels  
lower than those observed with rhEPO  (Holdstock , 2016) . 
3.3.3.  Overall Benefit:Risk Conclusion  
Daprodustat demonstrates a positive benefit vs. risk balance based on the evidence as 
follows.  In clinical trials up to 24 weeks in duration, daprodustat maintained Hgb to 
target range in participant s with anemia associated with CKD (both nondialysis 
dependent ( ND) and hemodialysis dependent ( HD)) with a safety profile consistent with 
the patient population.  
This protocol employs precautions to mitigate kno wn and potential risks to enrolled 
participant s (See  Appendix 3).  Given these precautions, as well as the potential benefit 
that daprodustat holds for the treatment of anemia associated with CKD compared to the 
current standard, the overall benefit: risk bal ance is considered to be positive.  
4. OBJECTIVES AND ENDPO INTS  
Objectives  Endpoints  
Primary  
• Compare the efficacy of daprodustat to 
rhEPO (i.e., epoetin alfa or darbepoetin 
alfa) on iron absorption  • Difference in fractional oral iron 
absorption (%) between daprodustat and 
rhEPO  
Secondary  
• Characterize the effect of  daprodustat or  
rhEPO on markers of iron status  • Change from baseline (Day 1) at 14 and 
28 days following treatment with 
daprodustat or rhEPO  in serum iron, 
transferrin, transferrin saturation, soluble 
transferrin receptor, ferritin, hepcidin and 
erythroferrone  
• Characterize the effect of daprodustat or 
rhEPO on indices of erythropoiesis  • Change from baseline (Day 1) at 14 and 
28 days following treatment with 
daprodustat  or rhEPO  in Hgb, hematocrit, 
red blood cell number, mean corpuscular 
volume, reticulocyte Hgb and 
reticulocyte number  
Safety  
• Assess safety and tolerability  • Incidence and severity of adverse events 
and serious adverse events  
• Reasons for discontinuation of study 
medication  
• Vital signs assessments  
 
TMF-13854840  CONFIDENTIAL   
  201771  
 15 
 5. STUDY DESIGN  
5.1. Overall Design  
This study will be a randomized, repeat dose, open label, two period cross -over study in 
adult, male and female participants with anemia associated with chronic kidney disease 
who are not on dialysis currently treated with stable doses (≤ 50% change in 4 -weekly 
dose) for at least 8 weeks prior to  and including the  screening period, of rhEPO (i.e., 
epoetin alfa or darbepoetin alfa ). 
Sufficient participants will be enrolled such t hat at least 12 participants comprise the 
Evaluable Population (See Section 10.3.1.3 ). 
The study design is outlined in Figure 2. 
Figure 2 Study Design  
 
• There will be a 4 -week screening period in order to confirm that participants have 
stable Hgb levels  and to assess entry criteria  
• A 28-day Treatment Period  1 for incorporation of iron into erythrocytes  while on 
randomized study treatment  
• A 28-day Treatment P eriod  2 for a second incorporation of iron into erythrocytes  
while on randomized study treatment  
• A follow -up visit 14 ± 3 days after completing treatment.  
Participants will be randomly assigned either to remain on their current therapy  (either 
epoetin alfa or darbepoetin alfa)  or be switched to daprodustat for Treatment Period 1.  
For assessment of inc orporation of iron into erythrocytes, enrolled participants will be 
administered ferrous sulfate containing a stable isotope of iron (57Fe or 58Fe) orally in a 
randomized fashion  following 2 weeks of administration o f randomized  study treatment.  
Thus, there are 4 possible t reatment sequence s as shown in Table 1.  Two weeks 
following oral iron administration a blood sample will be taken in order to a ssess the 
incorporation of the iron isotope into red blood cells by thermal ionization mass 

TMF-13854840  CONFIDENTIAL   
  201771  
 16 
 spectrometry (TIMS) using  published methods ( IAEA  Human Health Series No. 21 , 
2012 ). 
At Day 29 participants will be crossed over  to the study treatment they did not receive in 
Treatment Period 1, i.e., for participants that remained on their current therapy they 
would be switched to daprodustat, while subjects that had been admini stered daprodustat 
would be switched back to their previous therapy  at the dose prior to randomization .  At 2 
weeks following initiation of dosing, participants will again be administered ferrous 
sulfate containing the stable iron isotope not administered following the assessment in 
Treatment Period  1 orally .  Two weeks following oral iron administration a blood sample 
will again be taken in order to assess the incorporation of the iron isotope into red blood 
cells by TIMS.  
Participants will attend a follow -up visit 14 ± 3 days following the final blood sample for 
assessment of red blood cell iron.  
Table 1 Possible Treatment Sequences  
 Sequence A  
N=3 Sequence B  
N=3 Sequence C  
N=3 Sequence D  
N=3 
Treatment Period 
1 rhEPO  
57Fe rhEPO  
58Fe Daprodustat  
57Fe Daprodustat  
58Fe 
Treatment Period 
2 Daprodustat  
58Fe Daprodustat  
57Fe rhEPO  
58Fe rhEPO  
57Fe 
 
5.2. Number of Participants  
Sufficient participants will be enrolled such that at least 12 participants comprise the 
Evaluable  Population (See Section  10.3.1.3 ). 
5.3. Participant and Study Completion  
A participant is considered to have completed the study if he/she has completed all 
phases of th e study including the follow -up visit.  
The end of the study is def ined as the date of the last visit of the last participant in the 
study.  
5.4. Scientific Rationale for Study Design  
This study will use a randomized, repeat dose, open label, two period  cross over design in 
adult, ND, male and female participants with anemia associated with chronic kidney 
disease currently treated with stable rhEPO doses (≤ 50% change in 4 -weekly dose) for at 
least 8 weeks prior to and  including the screening period . 
• This will be an open label study as oral iron absorption is an objective measure 
and unlikely to be influenced by the participant’s knowledge of the treatment 
administered.  Additionally, blinding of treatment would be difficult as rhEPO is 
TMF-13854840  CONFIDENTIAL   
  201771  
 17 
 administered by su bcutaneous injection, while daprodustat is administered orally 
once daily as a tablet.  
• Iron absorption will be assessed over a 2 week period commencing after 2 weeks 
of study treatment , a period of time when it is anticipated that any changes in oral 
absorption mediated by changes in expression of HIF -dependent D cytB and 
DMT1 will be apparent ( Shah , 2009) . 
• This study will use a cross over design, with oral iron abso rption assessed in each 
participant following both rhEPO and daprodustat administration, in order for 
each participant to serve as their own control.  
• Participants will need to be currently treated with stable doses (≤ 50% change in 
4-weekly dose) of rhEPO  for at least 8 weeks prior to and including the screening 
period .  Additionally, participants need to have stable Hgb levels for the 4 weeks 
of screening.  Finally, participants will be switched from their current rhEPO to 
daprodustat using a switching algorithm that was designed to result in no change 
in Hgb levels.  All of these aspects are intended to minimize any potential for a 
change in erythropoiesis during the course of the study in order to minimize any 
potential  change in oral iron absorption due  to a change in erythropoiesis ( Skikne , 
2000) .   
• The planned population is participants currently on rhEPO for anemia associated 
with chronic kidney disease that are non -dialysis dependent.  This population was 
chosen as those  most likely to be administered oral iron therapy for the treatment 
of anemia .  Additionally,  as oral iron is inferior to IV iron likely due  to elevated 
levels of hepcidin and pro -inflammatory cytokines that restr ict intestinal iron 
absorption , this is the population most likely to benefit from an increase in oral 
iron absorption  (Macdougall , 2016). 
• This study uses iron incorporation into erythrocytes in order to assess oral iron 
absorption.  While it is appreciated that changes in erythrocyte iron conte nt can be 
due to many factors,  erythrocyte iron content is a well -recognized  surrogate for 
iron absorption ( IAEA  Human Health Series No. 21 , 2012) .  Additionally, 
fractional iron absorption as an endpoint allows for comparison to studies in non -
anemic participant s. 
• At present, three methodologies are primarily r ecognized for assessing fractional 
iron absorption : fecal recovery of the ingested isotope, plasma appearance of the 
ingested isotope and iron incorporation into erythrocytes  following oral ingestion .  
Of the three, the most frequently used approach is iro n incorporation into 
erythrocytes using single or multiple oral labels as it is more sensitive than either 
the fecal recovery or plasma appearance methods  (IAEA  Human Health Series 
No. 21 , 2012) .  The majority (80%) of the iron that is absorbed is incorporated 
into red blood cells in Hgb, a process which occurs over 10 to 12 days.  Once 
incorporated, the iron is stable for the lifespan of the red blood cell, a period of  up 
to 120 days in non -anemic participant s and approximately 70 days in individuals 
with chronic kidney disease.  
• Iron absorbed from the diet is obtained from animal -based sources, and is known 
as heme iron, while plant -based iron is non -heme iron.  This st udy will assess the 
TMF-13854840  CONFIDENTIAL   
  201771  
 18 
 absorption of non -heme iron as most of the understanding of iron absorption is 
related to non -heme iron which typically comprises the majority of dietary and 
supplemental iron.  
• ND-CKD patients which have elevated levels of C -reactive pr otein (CRP) and 
hepcidin typically experience poor intestinal iron absorption ( Macdougall , 2014).  
Therefore, hsCRP will be assessed at screening for eligibility in order to minimize 
the recruitment of participants with poor intestinal iron absorption due to 
inflammation.  
• Finally, s table isotopic iron will be administered in the fasted state as the fraction 
of iron absorbed in the fasted state is typica lly much higher than that which occurs 
when a component of a mixed meal.  A recent publication using this methodology 
in 18 healthy, adult female participant s reported an average absorption ± SD of 
14.71 ± 10.7% in the fasted state compared to 3.63 ± 6.5% in the fed state  
(Young , 2009 ).  In this regard, it is considered that a 30% change in oral iron 
absorption is clinically relevant.  
5.5. Dose Justification  
• The dose of rhEPO in this study will be the stable doses (≤ 50% change in 4 -
weekly dose) administered for at least 8 weeks prior to and including the 
screening period . 
• The goal of the starting doses of daprodustat in this study is to maintain Hgb 
levels achieved on th e prior rhEPO dose so that, on average, there is no change 
from baseline Hgb.  Starting doses of 1, 2 or 4 mg of daprodustat are estimated to 
maintain Hgb levels observed with participant’s prior rhEPO therapy based on 
population dose -response longitudinal  modelling of Hgb data collec ted across the 
Phase 2 program ( GlaxoSmithKline Document Number 2015N248947_00 , 2016 ). 
6. STUDY POPULATION  
Prospective approval of protocol devi ations to recruitment and enrol ment criteria, also 
known as protocol waivers or exemptions, is not permitted.  
6.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all the following criteria apply:  
Age 
1. Participant must be at least 18 years of age inclusive, at the time of signing the 
informed consent.  
Type of Participant and Disease Characteristics  
2. Participants who are Stage 3, 4 or 5 CKD  (confirmed at Week -4 only)  defined by 
eGFR using the CKD Epidemiology Collabo ration (CKD -EPI) formula ( Levey , 
2009) .  See the Study R eference Manual ( SRM ) for details on calculation.  
TMF-13854840  CONFIDENTIAL   
  201771  
 19 
 3. Participants who are currently treated with stable doses (≤ 50% change in 4 -weekly 
dose) for at least 8 weeks prior to and including the screening period, of rhEPO (i.e., 
epoetin alfa or darbepoetin alfa) . 
4. Participants with Hgb levels between 9.0 and 11.5 g/dL, inclusive , who meet  the Hgb 
stability criteria  as outlined in Section 6.2.1 . 
5. Participants may be on stable maintenance oral iron supplementation  (<50% change 
in overall dose and compliance of 80% of prescribed doses in the 4 weeks prior to 
and including the screening period) .  If participants have been on IV iron, then 
participants will not have received IV iron for 8 weeks prior to  the Day 1 visit. 
Sex 
6. Male or female  
a. Female participants:  
A female participant is eligible to participate if she is not pregnant (see Appendix  7), 
not breastfeeding, and at least one of the following conditions applies:  
(i) Not a woman of childbearing potential (WOCBP) as defined in Appendix  7 
OR 
(ii) A WOCBP who agrees to follow the contraceptive guidance in Appendix  7 
during the treatment period to the follow -up visit . 
Informed Consent  
7. Capable of giving signed informed consent as described in Appendix 5 which 
includes compliance with the requirements and restrictions listed in the informed 
consent form (ICF) and in this protocol.  
6.2. Exclusion Criteria  
Participants are excluded from the study if an y of the following criteria apply:  
Medical Conditions  
1. On dialysis or clinical evidence of impending need to initiate dialysis within 90 days 
after study start (i.e., Day 1).  
2. Planned kidney transplant within 3 months after study start.  
3. A positive test for HIV antibody.  
Prior/Concomitant Therapy  
4. History of severe allergic or anaphylactic reactions or hypersensitivity to excipients 
in the investigational products (see Daprodustat IB for list of excipients).  
5. Use of any prescription or non -prescription drugs or  dietary supplements that are 
prohibited from screening until the end of Treatment Period 2  (see Section 7.7.2 ). 
6. Planned or current administration o f Mircera (methoxy PEG -epoetin beta).  
TMF-13854840  CONFIDENTIAL   
  201771  
 20 
 Prior/Concurrent Clinical Study Experience  
7. The participant has participated in a clinical trial and has received an experimental 
investigational product within the prior 30 days or 5 half lives, whichever is longer,  
from screening through Day 1.  
Diagnostic assessments  
8. At or below the lower limit of the reference range at screening for Vitamin B 12 (may 
rescreen in a minimum of 8 weeks).  
9. Ferritin outside the range between 100 and 500 ng/mL, inclusive, at screening.  
10. Transferrin saturation (TSAT) outside the range between 15 % and 40%, inclusive, at 
Screening.  
11. Folate < 2.0 ng/mL (4.5 nmol/L; may rescreen in a minimum of 8 weeks) at 
screening.  
12. High sensitivity C-reactive protein ( hsCRP) ≥ 20 µg/mL at screening.  
Other Exclus ions 
13. Myocardial infarction or acute coronary syndrome: ≤ 8 weeks prior to screening 
through Day 1.  
14. Hospitalization for greater than 24 hours: ≤ 8 weeks prior to screening through Day 1  
15. Stroke or transient ischemic attack  ≤ 8 weeks prior to screening throug h Day 1.  
16. Class IV heart failure , as defined by the New York Heart Association (NYHA) 
functional classification system.  
17. Current uncontrolled hypertension as determined by the investigator.  
18. QT interval corrected for heart rate using Bazett’s formula ( QTcB ): QTcB > 500 
msec, or QTcB > 530 msec in participa nts with Bundle Branch Block.  There is no 
QTc exclusion for participants with a predominantly paced rhythm.  
19. Active chronic inflammatory disease that could impact erythropoiesis.   A partial list 
can be found in the Study Reference Manual (SRM).  
20. History of bone marrow aplasia or pure red cell aplasia.  
21. Conditions, other than anemia associated with  chronic kidney disease,  which  can 
affect erythropoiesis .  A partial list can be found in the SRM.  
22. Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease OR 
clinically significant GI bleeding from ≤ 4 weeks prior to screening through Day 1.  
23. Liver disease (any of the following):  
• Alanine transaminase (ALT) > 2x upper limit of normal (ULN; screen ing only)  
• Bilirubin > 1.5x ULN ( screening only)  
NOTE:  Isolated bilirubin > 1.5 x ULN is acceptable if bilirubin is fractionated and 
direct bilirubin < 35%  
TMF-13854840  CONFIDENTIAL   
  201771  
 21 
 • Current or chronic history of liver disease or  known hepatic or biliary abnormalities 
(with the excep tion of Gilbert's syndrome or asymptomatic gallstones) . 
24. Major surgery (excluding vascular access surgery) within the 8 weeks prior to 
screening through Day 1 or planned during the study.  
25. Blood transfusion within 8 weeks prior to screening through Day 1, or  an anticipated 
need for blood transfusion during the study.  
26. Clinical evidence of an acute infection, or history of infection requiring IV antibiotic 
therapy from 4 weeks prior to screening through Day 1.  
NOTE:  Prophylactic antibiotics  are allowed.  
27. History of malignancy within the two years prior to screening through Day 1 or 
currently receiving treatment for cancer, with the exception of localized squamous 
cell or basal cell carcinoma  of the skin definitively treated 12 weeks prior to Day 1 . 
28. Any oth er condition, clinical or laboratory abnormality, or examination finding that 
the investigator considers would put the participant  at unacceptable risk, which may 
affect study compliance or prevent understanding of the aims or investigational 
procedures or  possible consequences of the study.  
6.2.1.  Hgb Stability Criteria  
Entry into the study requires a stable Hgb between 9.0 - 11.5 g/dL . 
• This criterion  is assessed  from an average of three  Hgb values obtained via a 
validated point -of-care device to measure Hgb (Hem oCue) on site during the 
screening period at Week -4, Week -2 and on Day 1. 
• The Hgb stability assessment is the difference  between the maximum and 
minimum  values of the three Hgb measurements obtained between  Week -4 and 
Day 1 . 
A decision algorithm for Hgb stability is shown in Figure 3. 
TMF-13854840  CONFIDENTIAL   
  201771  
 22 
 Figure 3 Hgb Stability Criteria  
 
6.3. Lifestyle Restrictions  
No lifes tyle restrictions are required.  
6.4. Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomized .  A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory author ities.  Minimal information includes 
demography, screen failure details, eligibility criteria, and any serious adverse events 
(SAE s). 
Individuals who do not meet the criteria for participation in this study (screen failure) 
may be rescreened.  
 

TMF-13854840  CONFIDENTIAL   
  201771  
 23 
 7. TREATMENTS  
Study treatment is defined as an y investigational treatment(s), marketed product(s), 
placebo , or medical device (s) intended to be administered to a study participant according 
to the study protocol.  
Participants at study entry will discontinue their rhEPO therapy (i.e., epoetin alfa or 
darbepoetin alfa) prior to randomization so that the randomization date (Day 1) should 
coincide, as closely as possible, with the date of the next scheduled rhEPO 
administration.  Examples of switching are provided in the SRM.  
7.1. Treatments Administered  
Study 
Treatment 
Name:  Daprodustat  rhEPO 
(epoetin alfa 
OR 
darbepoetin 
alfa)  57Fe 58Fe 
Dosage 
formulation:  Tablet  Solution for 
injection  57FeSO 4  
Oral solution  58FeSO 4/ 56FeSO 4  
Oral solution  
Unit dose 
strength(s)/ 
Dosage level(s):  1 mg, 2 mg, 
4 mg tablet 
strengths/1 mg, 
2 mg, 4 mg 
dosage levels  rhEPO is 
commercially 
available in 
various single -
dose vials and 
single -dose 
prefilled 
syringes  57FeSO 4 
(containing 10 
mg of 57Fe)  
 
10 mg total dose 
of Fe   58FeSO 4 
(containing 3 mg  
of 58Fe)  
56FeSO 4 
(containing 7 mg  
of 56Fe) 
10 mg total dose  
of Fe  
Route of 
Administration  Oral Subcutaneous 
injection  Oral Oral 
Dosing 
instructions:  1 tablet to be 
taken daily 
without regard 
for food  As per product 
labelling  Full dosing 
instructions can 
be found in the 
SRM  Full dosing 
instructions can 
be found in the 
SRM  
Packaging and 
Labeling  Study Treatment 
will be provided 
in a bottle . Each 
bottle will be 
labeled as 
required per 
country 
requirement.  As per product 
labelling  N/A N/A 
Manufacturer  GSK  Amgen  Formulated  by 
extemporaneous 
compounding  Formulated  by 
extemporaneous 
compounding  
TMF-13854840  CONFIDENTIAL   
  201771  
 24 
 7.1.1.  Daprodustat Dosing Information  
Doses of daprodustat to be administered are based on the rhEPO dose at randomization 
(Day 1) as described in Table 2. 
Table 2 Daprodustat Doses  
Darbepoetin alfa  
(µg/4 wk SC/IV)  Epoetin alfa  
(convert SC to IV 
U/week)1 Daprodustat dose  
(mg, once daily)  
20 to 30 1500 to 2000  1 
>30 to 300  >2000 to <20000  2 
>300  ≥20000  4 
1 Standardized rhEPO IV dose (U/week) = 161 /113 x (epoetin SC dose 
(units)/frequency)  
 
7.1.2.  rhEPO  Dosing Information  
Participants are required to be currently treated with stable doses (≤ 50% change in 4 -
weekly dose) of rhEPO for at least 8 weeks prior to and including the screening period .  
The dose of rhEPO to be administered during the study as randomized study treatment 
will be the rhEPO dose at randomizatio n (Day 1) .  This dose is to be administered 
whether a participant is randomized to rhEPO on Treatment Period 1, or is switching 
back to rhEPO following 4 weeks of administration of daprodustat on Treatment Period 
2. 
7.1.3.  57Fe Dosing Information  
An oral solution  will be administered containing  10 mg of 57Fe as ferrous sulfate.  Exact 
doses will be measured, calculated, and captured for each individual participant. The 
solution is to be taken following an overnight fast.   Further d etails will be outlined in the 
compounding document and SRM.  
7.1.4.  58Fe Dosing Information  
An oral solution will be administered containing 3 mg of 58Fe as ferrous sulfate with  7 
mg of 56Fe as ferrous sulfate (natural abundance F e).  Exact doses will be measured, 
calculated, and captured for each individual participant.  The solution s are to be taken 
following an overnight fast.  Further details will be outlined in the compounding 
document and SRM.  
TMF-13854840  CONFIDENTIAL   
  201771  
 25 
 7.2. Dose Modification  
No dosage modification is anticipated  in this study.   However, if it becomes med ically 
necessary to adjust the dose of either rhEPO or daprodustat, the participant is to be 
withdrawn from the study.  
7.3. Method of Treatment Assignment  
All participants will be centrally randomized using an Interactive Voice/Web Response 
System (IVRS/IWRS).  Before the study is initiated, the telephone number and call -in 
directions for the IVRS and/or the log in information & directions for the IWRS will be 
provided to each site.  
7.4. Blinding  
This is an open -label study; potential bias will be reduced by using ce ntral randomization.   
Further, fractional iron absorption is an objective  endpoint, such that participant 
knowledge of the treatment received is unlikely to affect the results.  
7.5. Preparation/Handling/Storage/Accountability  
• The investigator or designee must confirm appropriate temperature conditions 
have been maintained during transit for all study treatment received and any 
discrepancies are reported and resolved before use of the study treatment.  
• Only participants enrolled in the study may receive study tre atment and only 
authorized site staff may supply or administer study treatment. All study 
treatments must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions 
with acc ess limited to the investigator and authorized site staff.  
• The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study treatment accountability, reconciliation, and 
record maintenance (i .e., receipt, re conciliation, and final disposition records).  
• Further guidance and information for the final disposition of unused study 
treatment are provided in the SRM . 
• Under normal conditions of handling and administration, study treatment is not 
expected to pose sign ificant safety risks to site staff .  Take adequate precautions 
to avoid direct eye or skin contact and the generation of aerosols or mists.  In the 
case of unintentional occupational exposure notify the monitor, Medical Monitor 
and/or GSK study contact.  
• A Material Safety Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by local laws, or is available 
upon request from GSK.  
TMF-13854840  CONFIDENTIAL   
  201771  
 26 
 7.6. Treatment C ompliance  
• When the individual dose for a participant  is prepared from a bulk supply, the 
preparation of the dose will be confirmed by a second member of the study site 
staff.  
• When participants are  dosed at the site, they will receive study treatment directly 
from the investigator or designee, under medical supervision.  The date and time 
of each dose administered in the clinic will be recorded in the source documents.  
The dose of study treatment a nd study participant  identification will be confirmed 
at the time of dosing by a member of the study site staff other than the person 
administering the study treatment.  
• When participants self -administer study treatment(s) at home, compliance will be 
assess ed through querying the participant during  the site visits and documented in 
the source documents and eCRF.  A record of the study treatment  dispensed to 
and taken by each participant  must be maintained and reconciled with study 
treatment and compliance re cords.  Treatment start and stop dates, including dates 
for treatment delays and/or dose reductions will also be recorded in the eCRF.  
7.7. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant i s receiving at the time of 
enrolment or receives during the study must be recorded along with:  
• reason for use  
• dates of administration including start and end dates  
• dosage information including dose and frequency  
The Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy.  
7.7.1.  Permitted Medications and Non -Drug Therapies  
Unless specified as a prohibited medication in Section  7.7.2 , all concomitant medications 
should be considered permitted provided they are not contraindicated for the individual 
participant  concerned.  
Participants are to be advised to maintain use of the  following medications at a consistent 
dosage and frequency:  
• Oral iron supplementation  (except ferric citrate, which is prohibited ; see Section 
7.7.2 ) 
• Acid -reducing agents (e.g., H 2 receptor antagonists, proton pump inhibitors, 
antacids)  
TMF-13854840  CONFIDENTIAL   
  201771  
 27 
 7.7.2.  Prohibited Medications and Non -Drug Therapies  
Use of any of the following prescription drugs from screening (Week -4) until the end of 
Treatment Period 2  is prohibit ed and will constitute a protocol deviation : 
• Strong inhibitors of CYP2C8 (e.g., gemfibrozil , high dose clopidogrel [300 mg] ) 
• Strong inducers of CYP2C8 (e.g., rifampin/rifampicin)  
• The oral iron supplement ferric citrate  
• Intravenous administration of iron  
• Any rhEPO other than epoetin alfa or darbepoetin alfa  
7.7.3.  Standard of Care  
During the study, investigators are expected to monitor the participant ’s overall clinical 
status to ensure standards of care are met to enable consistency of practice with KDIGO  
guidel ines or local equivalent.  
7.8. Treatment after the End of the Study  
Participant s will not receive any additional treatment from GSK after completion of the 
study because the indication being studied is not life threatening or seriously debilitating 
and other treatment options are available.  
The investigator is responsible for ensuring that consideration has been given to the post -
study care of the participant ’s medical condition.  
8. DISCONTINUATION CRIT ERIA  
8.1. Discontinuation of Study Treatment  
Participants that discontinue study treatment should be withdrawn from the study.   See 
Section 8.2 for a description of withdrawal procedures . 
8.1.1.  Liver Chemistry Stoppin g Criteria  
Liver chemistry stopping and increased monitoring criteria  have been designed to 
assure participant safety and evaluate liver event  etiology.  
Discontinuation of study treatment for abnormal liver tests is required when:  
• a participant meets one of the conditions outlined in Figure 4 
OR 
• when  in the presence of abnormal liver chemistries not meeting protocol -specified 
stopping rules, the investigator believes study treatment discontinuation  is in the 
best interest of the participant.  
TMF-13854840  CONFIDENTIAL   
  201771  
 28 
 Figure 4 Phase II I-IV Liver Chemistry Stopping and Increased Monitoring 
Algorithm  
Continue Study Treatment 
Discontinue Study Treatment Plus 
Bilirubin≥2x
ULN (>35% 
direct ) or plus
INR>1.5, if 
measured*
Possible  
Hy’s LawALT≥3xULNALT
≥8xULNPlus
Symptoms of 
liver injury
or 
hypersensitivityNo
Yes
Yes YesNo No NoSee algorithm 
for continued 
therapy with 
increased liver 
chemistry 
monitoring
Yes
*INR value not applicable to subjects on anticoagulants ALT 
≥3xULN 
but 
<8xULNYes
➢Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
➢Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5, if measured*  
 
Liver Safety Required Actions and Follow up Assessments Section can be found in 
Appendix 2 . 
8.2. Withdrawal from the Study  
• A participant may withdraw from the stu dy at any time at his/her own request or  
may be withdrawn at any time at the discretion of the investigator for safety, 
behavioral, compliance or administrative reasons.  
• If the participant withdraws consent for disclosure of future information, the 
sponsor  may retain and continue to use any data collected before such a 
withdrawal of consent.  
• If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site 
study  records.  
• Participants that withdraw /are withdrawn  from the study  treatment  are encouraged 
to attend the follow -up visit 14 ± 3 days following discontinuation of study 
treatment.  Assessments to be conducted are listed in the SoA  (Section 2). 
 
 
TMF-13854840  CONFIDENTIAL   
  201771  
 29 
 8.2.1.  Criteria for Permanent Discontinuation from Study Treatment and 
Early  Withdrawal  
Participant s must permanently discontinue study treatment  and be withdrawn from the 
study for the following reasons:  
• Meets Hgb stopping criteria (See Section 8.2.1.1 ) 
• Meets iron stopping criteria (See Sect ion 8.2.1.2 ) 
• If it becomes medically necessary to adjust the dose of either rhEPO or 
daprodustat  
• Receives a blood transfusion  
• Receives a kidney transplant  
• Becomes pregnant or intends to become pregnant d uring the study  
• Active GI bleeding  
• Diagnosis of cancer, with the exception of squamous cell or basal cell carcinoma  
• Liver chemistry abnormalities exceeding the threshold criteria (See Section 8.1.1 ) 
• Use of prohibited medication (See Section 7.7.2 ) 
• Active chronic inflammatory disease that could impact erythropoiesis  
• Any new diagnosis of hematological disease including those affecting platelets, 
white or red blood cells, coagulation dis orders, or any other cause of anemia of 
chronic disease other than renal disease  
8.2.1.1.  Hgb Stopping Criteria  
GSK will supply a point -of-care Hgb analyzer (HemoCue) to each site for rapid and 
convenient monitoring of Hgb levels and to ensure consistency of Hgb me asurements 
across sites participating in the study.  
Blood samples for measurement of Hgb concentrations via HemoCue will be collected 
and recorded in the eCRF.  Table 3 summarizes the Hgb values and corresponding a ction 
to be taken at each visit.  
TMF-13854840  CONFIDENTIAL   
  201771  
 30 
 Table 3 Hgb Stopping Criteria  
Hgb (g/dL) at visit  Action  
<7.5 Repeat HemoCue assessment on the same sample at 
same study visit to confirm; take average of 2 values.  If 
confirmed, permanently discontinue study treatment  and 
withdraw participant from the study.  
7.5 - <13.0  
With:  2.0 g/dL decrease  in Hgb 
over the previous 2 weeks   Repeat HemoCue assessment on the same sample at 
same study visit to confirm; take average of 2 values.  If 
confirmed, permanently discontinue study treatment and 
withdraw participant from the study.  
7.5 - <13.0  
With:  <1.0 absolute change in 
Hgb over the previous 2 
weeks  Continue study treatment.  
7.5 - <13.0  
With:  1.0 increase in Hgb over 
the previous 2 weeks  Repeat HemoCue assessment on the same sample at 
same study visit to confirm; take average of 2 values.  If 
confirmed, permanently discontinue study treatment  and 
withdraw participant from the study.  
13.0 Repeat HemoCue assessment on the same sample at 
same study visit to confirm; take average of 2 values.  If 
confirmed, permanently discontinue study treatment and 
withdraw participant from the study.  
 
8.2.1.2.  Iron S topping Criteria  
Participants must remain iron replete throughout the study, and should remain on  their 
regular oral iron supplement  as described in Section 7.7.1 . 
Based on the PI's clinical judgement in consultation with Medical Monitor, if the subject 
cannot be maintained on the same oral iron dose during the study treatment periods, the 
subject must  be withdrawn .  
8.3. Lost to Follow Up  
A participant  will be considered lost to follow -up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails t o return to the clinic for a 
required study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain w hether or not the participant wishes to 
and/or should continue in the study.  
• Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 
telephone calls and , if necessary, a certified letter to the participant’s last known 
TMF-13854840  CONFIDENTIAL   
  201771  
 31 
 mailing address or local equivalent methods).  These contact attempts should be 
documented in the participant’s medical record.  
• Should the participant continue to be unreachable, he/she wil l be considered to 
have withdrawn from the study with a prima ry reason of lost to follow -up. 
9. STUDY ASSESSMENTS AN D PROCEDURES  
• Study procedures and their ti ming are summarized in the SoA  (Section 2). 
• Protocol waiver s or exemptions are not allowed.  
• Immediate safety concerns should be discussed with the sponsor immediately 
upon occurrence or awareness to determine if the participant shoul d continue or 
discontinue study treatment.  
• Adherence to the study design requirements, including those specified in the SoA, 
is essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that 
potential par ticipants meet all eligibility criteria.  The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility or record reasons for screening failur e, as applicable.  
• Procedures conducted as part of the p articipant’s routine clinical management 
(e.g., Hgb levels ) and obtained before signing of ICF may be utilized for 
screening or baseline purposes provided the procedure met the protocol -specified 
criteria and was performed  within the time frame defined in the SoA  (Section 2). 
• The maximum amount of blood collected from each participant over the duration 
of the study, including any extra assessments that may be required, will not 
exceed 500 mL. 
• Repeat or unscheduled samples may be taken for safety reasons or for tec hnical 
issues with the samples.  
9.1. Efficacy Assessments  
Efficacy is not evaluated in this study . 
9.2. Adverse Events  
The definitions of an AE or SAE can be found in Appendix 6. 
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, 
or the participant's legally authorized representative).  
The investigator and any designees are responsible for detecting, documenting, and 
reporting events that meet  the definition of an AE or SAE and remain responsible for 
following up AE s that are serious, considered related to the study treatment or the study, 
or that caused the participant to discontinue the study treatment  (see Section 8). 
TMF-13854840  CONFIDENTIAL   
  201771  
 32 
 9.2.1.  Time Period and Frequency for Collecting AE and SAE 
Information  
• All SAE s will be collected from the start of treatment until the follow -up visit  at 
the time points specifi ed in the SoA (Section 2).  However, any SAEs assessed as 
related to study participation (e.g., study treatment, protocol -mandated 
procedures, invasive tests, or change in existing therapy) or related to a GSK 
product will be recorded from the time a subject consents to participate  in the 
study.  
• All AE s will be collected from the start of treatment until the follow -up visit  at 
the time points specified in the SoA ( Section 2). 
• Medical occurrences that begin before the start of study treatment but after 
obtaining informed consent will be recorded on the Medical History/Current 
Medical Conditions section of the eCRF  not the AE section.  
• All SAE s will be recorded and reported to th e sponsor or designee immediately 
and under no circumstance should this exceed 24 hours, as indicated in  Appendix 
6.  The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.  
• Investigators are not obligated to actively seek AEs or SAEs  in former study 
participants.  However, if the investigator learns of any SAE, including a death, at 
any time after a participant has been discharged from the study, and he/she 
considers the event to be reasonably related to the study treatment or study 
participation, the investigator must promptly notify the sponsor.  
• The method of recording, evaluating, and assessing cau sality of AEs and SAEs  
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 6. 
9.2.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AE and/or SAE.  Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occurrence.  
9.2.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the investigat or is required to proactively follow each 
participant at subsequent visits/contacts.  All SAEs, and non serious AEs of special 
interest (as defined in  Section  9.2.4 ), will be followed until the event is resolved, 
stabilized, otherwise  explained, or the participant is lost to follow -up (as defined in 
Section 8.3).  Further information on follow -up procedures is given in Appendix 6. 
9.2.4.  Adverse Events of Spe cial Interest (AESI)  
Adverse Events of Special Interest (AESI) have been identified based on non -clinical 
studies with daprodustat, clinical experience with rhEPOs , and current information 
regarding HIF -regulated pathways in mediating hypoxia -associated pathophysiology.  
The currently identified AESI for daprodustat are as follows:  
TMF-13854840  CONFIDENTIAL   
  201771  
 33 
 • Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis  
• Death, MI, stroke, heart failure, venous thromboembolism, thrombosis of vascular 
access  
• Cardiomyopathy  
• Pulmonary artery hypertension  
• Cancer -related mortality and tumor progression and recurrence  
• Esophageal and  gastric erosions  
• Proliferative retinopathy, macular edema, choroidal neovascularization  
• Exacerbation of rheumatoid arthritis  
• Worsening of hypertensio n 
9.2.5.  Regulatory Reporting Requirements for SAEs  
• Prompt notification by the investigator to the sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and 
the safety of a study treatment under clinical investigation are met.  
• The sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study treatment under clinical 
investigation.  The sponsor will comply with country -speci fic regulatory 
requirements relating to safety reporting to the regulatory authority, Institutional 
Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.  
• Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory requirements and 
sponsor policy and forwarded to investigators as necessary.  
• An investigator who receives an investigator safety report describing a SAE or 
other specific safety information (e.g., summa ry or listing of SAE) from the 
sponsor will review and then file it along with the IB and will notify the IRB/IEC, 
if appropriate according to local requirements.  
9.2.6.  Cardiovascular and Death Events  
For any cardiovascular events listed below  and all deaths, whether or not they are 
considered SAEs, specific Cardiovascular (CV) and Death sections of the eCRF will be 
required to be completed.  These sections include questions regarding cardiovascular 
(including sudden cardiac death ) and non -cardiovascular death.  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
TMF-13854840  CONFIDENTIAL   
  201771  
 34 
 • Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascularization  
The CV eCRFs are presented as queries in response to reporti ng of certain CV MedDRA 
terms.  The CV information should be recorded in the specific cardiovascular section of 
the eCRF within one week of receipt of a CV Event data q uery prompting its completion.  
The Death eCRF is provided immediately after the occurrence or outcome of death is 
reported.  Initial and follow -up reports regarding  death must be completed within one 
week of when the death is reported.  
9.2.7.  Possible Suicidality Related Adverse Events  
If during the study there is an occurrence of an AE or SAE which in the investigator’s 
opinion is possibly related to suicidality, the Possible Suicidality Related Adverse Events 
(PSRAE) eCRF form should be compl eted (in addition to the AE and SAE pages, as 
appropriate).  
This event may include, but is not limited to, one that involves suicidal ideation, a 
preparatory act toward imminent suicidal behavior, a suicide attempt, or a completed 
suicide.  The investigato r will exercise his or her medical and scientific judgment in 
deciding whether an event is possibly related to suicidality.  
9.2.8.  Pregnancy  
• Details of all pregnancies in female participants and the outcome for the neonate, 
if applicable, will be collected from  the start of study treatment.  
• If a pregnancy is reported, the investigator should inform GS K within 24 hours  of 
learning of the pregnancy and should follow the procedures outlined in Appendix  
7. 
• Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAE.  
9.3. Treatment of Overdose  
For this study, any dose of daprodustat  greater than 4 mg within a 24 -hour time period  
will be considered an overdose.  
There is no specific antidote for overdose with daprodustat. The expected manifestations 
of daprodustat overdosage include signs and symptoms associated with an excessive 
and/or rapid increase in Hgb concentration.  In the event of a suspected overdose, it  is 
recommended that the appropriate supportive clinical care be instituted, as dictated by the 
participant ’s clinical status.   Additionally, participant s should be monitored closely for 
CV events, increased heart rate and hematologic abnormalities . 
TMF-13854840  CONFIDENTIAL   
  201771  
 35 
 9.4. Safety  Assessments  
Planned time points for all safety assessments are provided in the S oA (Section 2). 
9.4.1.  Entry  Criteria  
Entry  criteria are to be assessed during the screening period, at Week -4, Week -2 and 
Day 1.  The timing for assessment of specific criteria are detailed in the S oA (Section  2), 
and are described in Table 4 
Table 4 Timing of Entry Criteri a Assessments  
Timing  Procedures  
Week -4 Informed consent, c omplete p hysical examination, medical history, 
demography, height, weight, vital signs, clinical safety laboratory assessments,  
pregnancy test,  eGFR, Hgb, HIV,  concomitant medications , rhEPO dose 
Week -2 Brief physical examination, Hgb, estradiol & FSH (as ne eded), ECG , folate, 
Vitamin B 12, hsCRP, ferritin, TSAT,  concomitant medications , rhEPO dose 
Day 1  Brief physical examination, weight, vital signs, Hgb, pregnancy test, 
concomitant medications , rhEPO dose 
 
9.4.2.  Physical Examinations  
• A complete physical examination will include, at a minimum, assessments of the 
skin, cardiovascular , respiratory , gastrointestinal and neurological systems.  
Height and weight will also be measured and recorded.  
• A brief  physical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascular system, and abdomen (liver and spleen).  
• Investigators should pay special attention to clinical signs related to previous 
serious illnesses.  
9.4.3.  Vital Signs  
• Oral temperature, pulse , respiratory rate, and blood pressure will be assessed.  
• Blood pressure and pulse measurements will be assessed in a seated position  
with a completely automated device.   Manual techniques will be used only if an 
automated device is not ava ilable.  
• Blood pressure and pulse measurements should be preceded by at least 5 
minutes of rest for the participant in a quiet setting without distractions (e .g., 
television, cell phones).  
• Vital signs (to be taken before blood collection for laboratory test s) will consist 
of 1 pulse and 3 blood pressure measurements (3 consecutive blood pressure 
TMF-13854840  CONFIDENTIAL   
  201771  
 36 
 readings will be recorded at intervals of at least 1  minute).  The average of the 3 
blood pressure readings will be recorded on the eCRF.  
9.4.4.  Electrocardiograms  
• ECG meas urements  will be obtained as outlined in the S oA (Section 2).  Full 
12-lead ECGs will be recorded with the  participant in a supine position.  Heart  
rate, PR interval, QRS duration, and QT (uncorrected) interval will be measured.  
QTcB will be calculated (machine read or manually) . 
• At each time point at which ECG s are required, two additional ECGs are 
required if the initial ECG measurement indicates prolonged QTc (see Section 
6.1) using the automated or manually calculated QTcB value.  The average 
QTcB value of all three ECGs will be used to det ermine eligibility.  
9.4.5.  Clinical Laboratory Assessments  
Refer to Appendix 4 for the list of protocol -required clinical chemistry and hematology 
(Table 8) and additional clinical laboratory assessments ( Table 9) to be performed and to 
the S oA (Section 2) for the timing and frequency.  
 
• The investigator must review the laboratory report, document this review, and 
record any clinically relevant changes occurring during the study in the AE 
section of the eCRF.  The laboratory reports must be filed with the source 
documents.   Clinically sign ificant abnormal laboratory findings are those which 
are not associated with the underlying disease, unless judged by the investigator 
to be more severe than expected for the participant's condition.  
• All laboratory tests with values considered clinically s ignificantly abnormal 
during participation in the study or within 48 hours  after the last dose of study 
treatment should be repeated until the values return to normal or baseline or are 
no longer considered significantly abnormal by the i nvestigator or med ical 
monitor.  
• If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified and the sponsor 
notified.  
• All protocol -required laboratory assessments, as defined in Appendix 4, must be 
conducted in accordance with the laboratory manual and the S oA. 
9.4.6.  Liver Chemistry Monitoring  
Clinical laboratory assessments for liver chemistry moni toring include ALT, AST, 
bilirubin and alkaline phosphatase.  R efer to the SoA ( Section 2) for the frequency of 
monitoring.  Additionally, all of these tests are also part of the Clinical Chemistry  
Assessments and will be performed at the timepoints where those assessments are done.  
These assessments must be conducted in accordance with the laboratory manual.  
9.5. Pharmacokinetics  
Pharmacokinetic (PK)  parameters are not evaluated in this study . 
TMF-13854840  CONFIDENTIAL   
  201771  
 37 
 9.6. Pharmacodynamics  
Pharmacodynamics  (PD)  are not evaluated in this study . 
9.7. Genetics  
A blood  sample for DNA isolation will be collected from participants who have 
consented to participate in the genetics analysis component of the study.  Participation is 
optional.  Participants who do not wish to participate in the genetic research may still 
participate in the study.  
In the event of DNA extraction failure, a replacement genetic blood sample may be 
requested from the participant. Signed informed consent will be required to obtain a 
replacement sample unless it was included in the original consent.  
See Appendix  8 for informa tion regarding genetic research .  Details on processes for 
collection and shipment and destruction of these samples can be found in the SRM . 
9.8. Biomarkers  
9.8.1.  Fractional oral iron absorption  
Venous blood samples will be collected for measurement of erythrocyte iron content at 
the times specified in the SoA  (Section 2).  Further details for blood collection 
procedures can be found in the SRM.  Calculations for fractional iron absorption will be 
included in the Reporting and Analysis Plan (RAP).  
9.8.2.  Iron status markers  
Markers of iron status (i.e., serum iron, transferrin, TSAT, soluble transf errin receptor, 
ferritin, hepcidin and erythroferrone ) will be assessed at the times listed in the SoA.  
Measurement of erythroferrone is dependent upon available of a suitable assay 
methodology, so may not be assessed.   All blood samples for iron status m arkers to be 
taken pre dose.  Further details for blood collection procedures can be found in the SRM.   
9.8.3.  Indices of erythropoiesis  
Indices of erythropoiesis (i.e., Hgb, hematocrit, red blood cell number, mean corpuscular 
volume, reticulocyte Hgb and reticulocyte number) are planned to be assessed at the 
times listed in the SoA  (Section 2).  Further details for blood collection procedures ca n be 
found in the SRM.  
9.9. Health Economics OR Medical Resource Utilization and 
Health Economics  
Health Economics/Medical Resource Utilization and Health Economics  parameters are 
not evaluated in this study.  
TMF-13854840  CONFIDENTIAL   
  201771  
 38 
 10. STATISTICAL CONSIDER ATIONS  
10.1.  Hypotheses  
The primary an alysis will test whether daprodustat is superior to rhEPO (i.e., epoetin alfa 
or darbepoetin alfa) according to the following statistical hypotheses:  
Null: The difference in fractional iron absorption between treatment arms (daprodustat - 
rhEPO (i.e., epoetin alfa or darbepoetin alfa) ) is equal to zero.  
Alternative: The difference in fractional iron absorption between treatment arms 
(daprodustat -rhEPO (i.e., epoetin alfa or darbepoetin alfa)) is not equal to zero.  
10.2.  Sample  Size Determination  
Sufficient pa rticipants will be enrolled such that at least 12 participants comprise the 
Evaluable Population (See Section 10.3.1.3 ). 
A sample size of 12 participants provides 90% power to detect a paired mean difference 
of 11% between the two treatment groups under an assumed between -participant standard 
deviation (SD) of 10.7%.  Note this is a conservative estimate of the SD of the paired 
differences as i t is based on a parallel design study ( Young , 2009).  
10.2.1.  Sample Size Sensitivity  
Table 5 illustrates the impact on power for the primary efficacy analysis based on 
alternative assumptions for the between participant SD and the expected difference 
between the treatment groups.  
Table 5 Impact on power based on alternative assumptions for the between 
participant SD and the expected difference between the treatment 
groups  
Between 
participant 
SD (%)  Expected difference between treatments in Fractional Iron Absorption 
(%) 
(daprodustat – rhEPO (i.e., epoetin alfa or darbepoetin alfa))  
7 9 11 13 15 
7 88% 98% >99%  >99%  >99%  
9 69% 88% 97% >99%  >99%  
10.7 54% 76% 90%  97% >99%  
12 43% 66% 82% 93% 98% 
14 35% 53% 70% 83% 92% 
 
10.2.2.  Sample Size Re -estimation  
No sample size re -estimation will be performed.  
TMF-13854840  CONFIDENTIAL   
  201771  
 39 
 10.3.  Data  Analysi s Considerations  
10.3.1.  Analysis Populations  
10.3.1.1.  Screened Population:  
This population consists of all participants who signed an ICF to participate in the clinical 
trial.  This population will be used for summarizing screening failure rates and reasons 
for sc reening failure.  
10.3.1.2.  Safety Population:  
This population consists of all randomized participants who received at least one dose of 
study treatment . This will be the primary population for the safety analyses.  
10.3.1.3.  Evaluable Population:  
This population consists of al l randomized participants who received study medication  
and completed the iron absorption assessment for both treatment periods .  This 
population will be used for the primary endpoint analysis.  
10.3.1.4.  Modified Intent to Treat (mITT) Population:  
This population consists of all randomized participants who received study medication 
and completed the iron absorption assessment at the end of the first treatment period.  
This population will be used for the sensitivity analysis of the primary endpoint.  
10.3.2.  Interim Analyses  
No interim analysis will be performed for this study.  
10.4.  Key Elements of Analysis Plan  
10.4.1.  Primary Analysis  
To compare daprodustat to rhEPO (i.e., epoetin alfa or darbepoetin alfa)  on fractional 
iron absorption, a mixed effect model will be fitted with fixed eff ect terms for treatment, 
sequence , period and iron isotope and a random effect for participant -within -sequence.  
The term sequence will consist of the four combinations of treatment and iron isotope 
assignments.  Point estimates and corresponding 95% confi dence intervals will be 
constructed for the  comparison of efficacy of daprodustat to rhEPO . 
A sensitivity analysis for this primary analysis will be performed using the same mixed 
modeling approach, except with the mITT population.  
Descriptive statistics (n, arithmetic mean, standard deviation, 95% CI, minimum, median 
and maximum) will be calculated for fractional iron absorption (%) at the Day  29 and 
Day 57 visits.  
TMF-13854840  CONFIDENTIAL   
  201771  
 40 
 10.4.2.  Secondary Analysis  
Descriptive statistics (n, arithmetic mean, standard deviation, 95% CI, minimum, median 
and maximum) will be calculated for iron markers and indices of erythropoiesis at each 
scheduled visit.  
Safety data will be presented in tabular and/or graphical format and summarized 
descriptively according to GSK’s Integrated Data Stan dards Library (IDSL) standards.  
Further details will be given in the Reporting Analysis Plan (RAP).  
TMF-13854840  CONFIDENTIAL   
  201771  
 41 
 11. REFERENCES  
Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic 
kidney disease. Nat Rev Nephrol.  2010; 6:699 -710. 
Besarab A, Prov enzano R, Hertel J, Zabaneh R, Klaus SJ, Lee T, Leong R, Hemmerich S, 
Yu KH, Neff TB. Randomized placebo -controlled dose -ranging and pharmacodynamics 
study of roxadustat (FG -4592) to treat anemia in nondialysis -dependent chronic kidney 
disease. Nephrol Dia l Transplant . 2015; 30:1665 -1673.  
GlaxoSmithKline Document Number 2015N248947_00. Phase 2 population 
pharmacodynamics analyses of GSK1278863 in anemic subjects with chronic kidney 
disease. 22 -APR -2016.  
GlaxoSmithKline Document Number RM2008/00267/07 Invest igator’s Brochure, 14 -
OCT -2015  
Haase VH. Regulation of erythropoiesis by hypoxia -inducible factors. Blood Rev.  2013; 
27:41 -53. 
Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, 
Lepore JJ, Cobitz AR. Four -week studies of oral hyp oxia-inducible factor -prolyl 
hydroxylase inhibitor GSK1278863 for treatment of anemia. J Am Soc Nephrol. 2016; 
27:1234 -1244.  
International Atomic Energy Agency (IAEA). Assessment of iron bioavailability in 
humans using stable iron isotope techniques. IAEA Human Health Series No. 21.  2012.  
Koury MJ, Haase VH. Anaemia in kidney disease: harnessing hypoxia responses for 
therapy. Nat Rev Nephrol.  2015; 11:394 -410. 
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, 
Eggers P, Van Lente F, Greene T, Coresh J. A new equation to estimate glomerular 
filtration rate. Ann Intern Med.  2009; 150:604 -612. 
Macdougall IC, Bircher AJ, Eckardt K -U, Obrador GT, Pollock CA, Stenvinkel P, 
Swinkels DW, Wanner C , Weiss G, Chertow GM. Iron management in chronic kidney 
disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) 
Controversies Conference. Kidney Int.  2016; 89:28 -39. 
Macdougall  IC, Bock A, Carrera F, Eckardt K -U, Gaillard C, Van Wyck D, Roubert B, 
Cushway T, Roger SD. The FIND -CKD study – a randomized controlled trial of 
intravenous iron versus oral iron in non -dialysis chronic kidney disease patients: 
background and rationale. Nephrol Dial Transplant 2014; 29:843 -850. 
Pfeffer MA, Burdmann EA, Chen C -Y, Cooper ME, de Zeeuw D, Eckart K -U, Feyzi JM, 
Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey 
P, Parving H -H, Remuzzi G, Singh AJ, Solomon, SD, Tot o R. A trial of darbepoetin alfa 
in Type 2 diabetes and chronic kidney disease. N Eng J Med.  2009;361:2019 -2032.  
TMF-13854840  CONFIDENTIAL   
  201771  
 42 
 Shah YM, Matsubara T, Ito S, Yim S -H, Gonzalez FJ. Intestinal hypoxia -inducible 
transcription factors are essential for iron absorption followi ng iron deficiency. Cell 
Metab. 2009; 9:152 -164. 
Skikne BS, Ahluwalia N, Fergusson B, Chonko A, Cook JD. Effects of erythropoietin 
therapy on iron absorption in chronic renal failure. J Lab Clin Med.  2000; 135:452 -458. 
Young MF, Glahn RP, Ariza -Nieto M, In glis J, Olbina G, Westerman M, O’Brien KO. 
Serum hepcidin is significantly associated with iron absorption from food and 
supplemental sources in healthy young women. Am J Clin Nutr.  2009; 89:533 -538. 
TMF-13854840  CONFIDENTIAL   
  201771  
 43 
 12. APPENDICES  
12.1.  Appendix 1: Abbreviations and Trademarks  
Table 6 List of Abbreviations  
Ab Antibody  
AE Adverse event  
AESI  Adverse events of special interest  
ALT  Alanine aminotransferase (SGPT)  
AST  Aspartate aminotransferase (SGOT)  
AUC  Area under the concentration -time curve  
BCRP  Breast Cancer Resistance Protein  
BUN  Blood urea nitrogen  
CI Confidence Interval  
CKD  Chronic kidney disease  
CKD -EPI Chronic kidney disease Epidemiology Collaboration  
CIOMS  Council for International Organizations of Medical Sciences  
Cmax  Maximum observed concentration  
CPK  Creatine phosphokinase  
CONSORT  Consolidated Standards of Reporting Trials  
CRF  Case Report Form  
hsCRP  High sensitivity C-reactive protein  
CV Cardiovascular  
CYP  Cytochrome P450 enzyme  
DcytB  Duodenal cytochrome b561  
dL deciliter  
DMT1  Divalent metal -iron transporter 1  
DNA  Deoxyribonucleic acid  
ECG  Electrocardiogram  
eCRF  Electronic Case Report Form  
eGFR  Estimated glomerular filtration rate  
EPO  Erythropoietin  
ESA  Erythropoiesis -stimulating agent  
FDA  Food and Drug Administration  
Fe Iron 
FPN Ferroportin  
FSH Follicle stimulating hormone  
g Gram  
GCP  Good Clinical Practice  
GDF15  Growth differentiation factor 15  
GI Gastrointestinal  
GSK  GlaxoSmithKline  
HBsAg  Hepatitis B surface antigen  
hCG  Human chorionic gonadotropin  
HD Hemodialysis dependent  
Hgb Hgb 
HIF Hypoxia -inducible factor  
HIV Human Immunodeficiency Virus  
HIPAA  Health Insurance Portability and Accountability Act  
TMF-13854840  CONFIDENTIAL   
  201771  
 44 
 HPLC  High performance liquid chromatography  
HRE  Hypoxia response element  
IAEA  International Atomic Energy Agency  
IB Investigator’s Brochure  
IC50 Half maximal inhibitory concentration  
ICH International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use  
ICF Informed Consent Form  
IEC Independent ethics committee  
IgG Immunoglobulin G  
IgM Immunoglobulin M  
IND Investigational new drug  
INR International normalization ratio  
IRB Institutional Review Board  
IU International units  
IUD Intrauterine device  
IUS Intrauterine system  
IV Intravenous  
KDOQI  Kidney Disease Outcomes Quality Initiative  
Kg Kilogram  
LDH  Lactate dehydrogenase  
LVEF  Left ventricular ejection fraction  
MCH  Mean corpuscular Hgb 
MCV  Mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory Activities  
mg Milligrams  
MI Myocardial infarction  
mL Milliliter  
mmHg  Millimeters of mercury  
MSDS  Material Safety Data Sheet  
msec  Milliseconds  
μM Micromolar  
ng Nanogram  
ND Nondialysis dependent  
NOAEL  No observed adverse effect level  
NYHA  New York Heart Association  
OATP  Organic anion transporting polypeptide  
PCI Potential clinical importance  
PD Pharmacodynamic  
PHD  prolyl -4-hydroxylases  
PHIs  Prolyl hydroxylase inhibitors  
PK Pharmacokinetic  
PRVP  Peak right ventricular pressure  
PSRAE  Possible Suicidality Related Adverse Events  
QTc Corrected QT interval  
QTcB  QT duration corrected for heart rate by Bazett’s formula  
RAP  Report and Analysis Plan  
RBC  Red blood cells  
rhEPO  Recombinant human erythropoietin  
RNA  Ribonucleic acid  
TMF-13854840  CONFIDENTIAL   
  201771  
 45 
 SAE  Serious Adverse Event  
SD Standard deviation  
SGOT  Serum glutamic -oxaloacetic transaminase  
SGPT  Serum glutamic pyruvic transaminase  
SO 4 Sulfate  
SoA Schedule of Assessments  
sPAP  systolic Pulmonary Artery Pressure  
SRM  Study Reference Manual  
SUSAR  Suspected unexpected serious adverse reactions  
TIMS  Thermal ionization mass spectrometry  
TF Transferrin  
TSAT  Transferrin saturation  
VEGF  Vascular endothelial growth factor  
ULN  Upper limit of normal  
UK United Kingdom  
US United States  
WBC  White blood cells  
WOCBP  Woman of Child Bearing Potential  
 
Trademark Information  
Trademarks of the GlaxoSmithKline 
group of companies   Trademarks not owned by the 
GlaxoSmithKline group of companies  
NONE   Aranesp (darbepoetin alfa)  
  Chiron RIBA  
  Epogen (epoetin alfa)  
  HemoCue  
  Procrit (epoetin alfa)  
  SAS 
  WinNonlin  
 
TMF-13854840  CONFIDENTIAL   
  201771  
 46 
 12.2.  Appendix 2: Liver Safety Required Actions and Follow up 
Assessments  
Phase I II-IV liver chemistry stopping criteria have been designed to assure participant  
safety and to evaluate liver event etiology (in alignment with the FDA premarketing 
clinical liver safety guidance).  
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM174090.pdf.  
Table 7 Phase III-IV liver chemistry stopping criteria and required follow -up 
assessments  
Liver Chemistry Stopping Criteria - Liver Stopping Event  
ALT -absolute  ALT  8xULN  
ALT Increase  ALT  5xULN but <8xULN  persists for 2 weeks  
ALT  3xULN but <5xULN  persists for 4 weeks  
Bilirubin1, 2 ALT  3xULN and bilirubin  2xULN (>35% direct bilirubin)  
INR2  ALT  3xULN and INR>1.5, if INR measured  
Cannot 
Monitor  ALT  5xULN but <8xULN and cannot be monitored weekly for 2 
weeks  
ALT  3xULN but <5xULN and cannot be monitored weekly for 4 
weeks  
Symptomatic3 ALT  3xULN associated with symptoms (new or worsening) 
believed to be related to liver injury or hypersensitivity  
Required Actions and Follow up Assessments following ANY Liver S topping 
Event  
Actions  Follow Up Assessments  
• Immediately discontinue study treatment  
• Report the event to GSK  within 24 hours  
• Complete the liver event eCRF and 
complete an SAE data collection tool if the 
event also meets the criteria for an SAE2 
• Perform liver event follow up assessments  
• Monitor the participant  until liver 
chemistries resolve, stabilize, or return to 
within baseline (Day 1 predose) (see 
MONITORING  below)  • Viral hepatitis serology4 
• Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend  
• Only in those with unde rlying chronic 
hepatitis B at study entry (identified by 
positive hepatitis B surface antigen) 
quantitative hepatitis B DNA and 
hepatitis delta antibody5. 
TMF-13854840  CONFIDENTIAL   
  201771  
 47 
 Liver Chemistry Stopping Criteria - Liver Stopping Event  
• Do not restart/rechallenge  participant  
 
MONITORING:  
For bilirubin or INR criteria:   
• Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin)  and 
perform liver event follow up assessments 
within 24 hrs  
• Monitor participants  twice weekly until 
liver chemistries resolve, stabilize or return 
to within baseline ( Day 1 predos e) 
• A specialist or hepatology consultation is 
recommended  
For All other criteria:  
• Repeat liver chemistries (include ALT, 
AST, alkaline phosphatase, bilirubin)  and 
perform liver even t follow up assessments 
within 24-72 hrs  
• Monitor participants  weekly until liver 
chemistries resolve, stabilize or return to 
within baseline  (Day 1 predose)  • Blood sample for pharmacokinetic (PK) 
analysis, obtained within 48 hrs after 
last dose6 
• Serum creatine phosphokinase (CPK) 
and lactate dehydrogenase (LDH).  
• Fractionate bilirubin, if total 
bilirubin2xULN  
• Obtain complete blood count with 
differential to assess eosinophilia  
• Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form  
• Record use of concomitant medications 
on the concomitant medications report 
form including acetaminophen, herbal 
remedies, other over the counter 
medications . 
• Record alcohol use on the liver event 
alcohol intake case report form  
For bilirubin or INR criteria:  
• Anti-nuclear antibody, anti -smooth 
muscle antibody, Type 1 anti -liver 
kidney microsomal antibodies, and 
quantitative total immunoglobulin G 
(IgG or gamma globulins).  
• Serum acetaminophen adduct HPLC 
assay (quantifi es potential 
acetaminophen contribution to liver 
injury in subjects with definite or likely 
acetaminophen use in the preceding 
week [ James , 2009]).   
• Liver imaging (ultrasound, magnetic 
resonance, or computerised 
tomography) and /or liver biopsy to 
evaluate liver disease; complete Liver 
Imaging and/or Liver Biopsy CRF 
forms.  
1 Serum bilirubin fractionation should be performed if testing is available.   If serum bilir ubin fractionation is not 
immediately available, discontinue study treatment for that subject if ALT  3xULN and bilirubin  2xULN.  Additionally, 
if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary bilirubin on d ipstick , 
indicating direct bilirubin elevations and suggesting liver injury . 
2 All events of ALT  3xULN and bilirubin  2xULN (>35% direct bilirubin) or ALT  3xULN and INR>1.5, if INR 
measured which may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding 
studies of hepatic impairment or cirrhosis) ; INR measurement is not required and the threshold value stated will not 
apply to subj ects receiving anticoagulants  
TMF-13854840  CONFIDENTIAL   
  201771  
 48 
 3 New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or  
eosinophilia)  
4 Includes : Hepatitis A IgM antibody; Hepatitis B surface antigen and Hepatitis B Core Antibody (IgM); Hepatitis C RNA; 
Cytomegalovirus IgM antibody;  Epstein -Barr viral capsid antigen IgM antibody (or if unavailable, obtain heterophile 
antibody or monospot testing) ;  Hepatitis E IgM antibody  
5 If hepatitis delta antibody assay cannot be performed, it can be replaced with a PCR of hepatitis D RNA virus (where 
needed) [ Le Gal , 2005]. 
6 PK sample may not be required for subjects known to be receiving placebo or non -GSK comparator treatments.  
Record the date/time of the PK blood sample draw and the date/time of the last dose of study treatment prior to blood 
sample draw on the CRF.  If the date or time of the last dose is unclear, provide the subject’s best approximation. If the 
date/time of the last dose cannot be approximated OR a PK sample cannot be collected in the time period indicated 
above, do not obtain a PK sample. Instructi ons for sample handling and shipping are in the SRM.  
References  
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen -Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos . 2009; 37:1779 -1784.  
Le Gal F, Gordian E, Affolabi D, Hanslik T, Alloui C, Deny P, Gault E. Quantification of 
hepatitis delta virus RNA in serum by consensus real -time PCR indicates different 
patterns of virological response to interferon  therapy in chronically infected patients. J 
Clin Microbiol.  2005; 43:2363 -2369.  
TMF-13854840  CONFIDENTIAL   
  201771  
49 
 12.3.  Appendix 3: Risk Assessment  
Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Excessive erythropoiesis leading to thrombosis 
and/or tissue ischemia  In animal studies, excessive erythropoiesis (Hgb/Hct > upper limit 
normal)  attributed to daprodustat was associated with vascular 
congestion, microthrombi, and tissue ischemia in a number of organs.  
In the phase 2 proof of concept study, a high incidence of 
discontinuation due to hemoglobin stopping criteria (Hgb > 13.5 g/dL 
or Hgb increased > 1 g/dL over any 2 -week period) was observed.  In 
non-dialysis subjects  administered 10 mg, 25 mg, 50 mg or 100 mg 
of daprodustat daily, a total of 21 of 61 subjects (34%) met these 
criteria.  In hemodialysis -dependent subjects administered either 10 
mg or 25 mg of daprodustat daily, a total of 8 of 31 subjects (26%) 
met thes e criteria.  
 
Phase 2 dose -ranging studies, and associated statistical and dose 
response modelling has informed Phase 3 dose rationale, starting 
doses, dose steps, and dose adjustment scheme to optimize Hgb 
management.  
 
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week 
treatment duration)]: Few subjects experienced a possible thrombosis 
related adverse event in the setting of excessive erythropoiesis 
[3/688 (0.5%) subjects on dap rodustat vs. 0/404 on rhEPO].  
 
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat  when dose is managed 
appropriately according to target Hgb. However, experience with 
daprodustat is currentl y insufficient to fully characterize this risk . • Specific eligibility criteria related to 
requirements for entry Hgb are detailed in 
Section 6.2.1 . 
• Hgb will be closely monitored throughout the 
dosing period as outlined in the SoA Table 
Section 2. 
• Specific guidance for discontinuation of 
daprodustat based on achieved Hgb i s 
provided in Section 8.2.1.1 . 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
Worsening hypertension  In a dog cardiovascular study, single oral doses of daprodustat (up to 
90 mg/kg) did not produce effects on blood pressure.  
Marketed rhEPO and its analogues have been associated with risks 
related to uncontrolled hypertension, including the need for initiation 
of or increases in antihypertensive therapy when used in patients with • Specific eligibility criteria related to blood 
pressure, including exclusion of subjects with 
uncontrolled hypertension, are  detailed in 
Section  6.2 . 
TMF-13854840  CONFIDENTIAL   
  201771  
50 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
anemia of CKD  (i.e. 25% Epogen, 27% Mircera, and 40% Aranesp 
treated patients with renal anemia required initiation or increase in 
their anti -hypertensive medications; hypertensive encephalopathy 
and seizures have been reported. The contribution of rhEPO -
associated hyp ertension to the unfavourable effects on 
cardiovascular outcomes remains uncertain).  
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 
Japanese phase 3 studies (52 -week treatmen t duration)]:  
o The majority (>90%) of subjects had baseline history of 
hypertension.  
o No meaningful difference was seen between treatment groups in 
AEs (preferred term) of “hypertension” [29/688 (4%) daprodustat 
vs. 19/404 (4%) rhEPO; 0.91 relative risk (RR ) (95% confidence 
interval: 0.5, 1.67)] or “blood pressure increased” [16 (2%) 
daprodustat vs. 7 (2%) rhEPO; RR 1.22 (0.48,3.11)]. Results 
were not substantively different between non -dialysis and 
haemodialysis subjects.  
o Although no clinically meaningful changes in blood pressure 
were observed, subjects in both treatment groups required 
increases in anti -HTN medications:  
o In the 24 -week global phase 2b studies, 25/170 (15%) 
of ND subjects receiving daprodustat vs. 18/80 (14%) 
control and 22/177 (12%) of HD subjects receiving 
daprodustat vs. 2/39 (5%) control.  
o In the 52 -week Japan phase 3 studies, 57/149 (38%) 
of ND subjects receiving daprodustat vs. 68/150 (45%)  
rhEPO and 51/136 (38%) of HD subjects receiving 
daprodustat vs. 66/135 (49%) for rhEPO.  
The data  received to date from completed clinical trials with 
daprodustat are insufficient to refute this risk.  • Blood pressure  will be closely monitored 
throughout the dosing period as outlined in 
the SoA Table Section 2. 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
51 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Death, MI, stroke, heart failure, thromboembolic 
events,  thrombosis of vascular access  at Hgb levels 
which are within the normal range (i.e. not 
polycythemic conditions)  Marketed rhEPO/ESAs have been associated with an increased risk 
for death and serious cardiovascular events when used in patients 
with anemia of CKD.  Clinical  studies with marketed rhEPO/analogs 
have suggested “higher” target hemoglobin, rate of hemoglobin rise 
of greater than 1 g/dL in any 2 -week period, and/or higher doses may 
contribute to these risks.  
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 
Japanese phase 3 studies (52 -week treatment duration)]: No 
meaningful difference was seen between treatment groups in the 
overall incidence of this AESI: [39/688 (5.5%) daprodustat vs. 25/404 
(6%) rhEPO; 0.92 relative risk (95% confidence interval: 0.55, 1.53)].  
Within this composite AESI, the most frequent event types were heart 
failure (at least 12 events daprodustat vs. at least 13 events rhEPO) 
and thrombosis (at least 14 events daprodustat vs. at least 8 event 
rhEPO); and a numerical imbalance was noted in events of 
myocardial ischemia (at least 7 events daprodustat vs. at least 1 
event rhEPO). The small number of events makes it difficult to draw 
any firm conclusions.  
The data received to date from completed clinical trials with 
daprodustat are insufficient to substantiate or refute this risk . • Specific eligibility criteria related to CV risk are 
outlined in Section  6.2. 
• Hgb will be closely monitored throughout the 
dosing period as outlined in the SoA (Section 
2). 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
Esophageal and gastric erosions  In animal studies, undesirable GI effects including emesis, abnormal 
feces and/or decreased food consumption/body weight loss and 
stomach erosions/ulcers with hemorrhage were observed with 
daprodustat.  
In rodents stomach erosions observed with intravenous and oral 
administration of daprodustat.  
Gender -averaged systemic exposure (AUC) at  the no observed 
adverse effect levels (NOAEL) are 3.3 -fold (monkeys) and 737 -fold 
(rats) above human exposure (25 mg daprodustat).  • Suspected GI bleeding or significant 
symptoms consistent with erosion should be 
investigated diagnostically (i.e. endoscopic 
examination) as clinically warranted.  
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
52 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
In clinical trials to date with daprodustat, mild -moderate GI signs and 
symptoms represent the most frequently reported ad verse event, 
however causal association has not been established.  
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 
Japanese phase 3 studies (52 -week treatment duration)] : No 
meaningful difference was seen between treatment groups in reports 
of this AESI [17 (2.7%) daprodustat vs. 10 (2.3%) rhEPO; 1.16 
relative risk (95% confidence interval: 0.52, 2.58)].  
Following review of clinical data received to date, GI erosions have 
not be en identified as a safety concern for daprodustat.  
Cancer -related mortality and tumor progression and 
recurrence  Marketed rhEPOs have been associated with increased risk of cancer 
related morbidity and mortality when used in patients with cancer.  
Administration of 60 mg/kg daprodustat to mice caused minimal 
increases in circulating VEGF while significant EPO increases were 
observed.  
In clinical studies with daprodustat up to 4 weeks duration, a dose -
ordered increase in VEGF plasma concentrations, an angiogenic 
factor that ha s been implicated in tumor growth, was observed at 
doses ranging from 10 to 150 mg.  In clinical studies up to 24 weeks 
duration at doses up to 25 mg, changes in VEGF plasma 
concentrations were variable but similar relative to control.  
Integrated AE data [ including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week 
treatment duration)]: No meaningful difference was seen between 
treatment groups in the occurrence of this AESI: [8/688 (1.1%) 
daprodustat vs. 4/404 (0 .9%) rhEPO; 1.14 relative risk (95% 
confidence interval: 0.31, 4.28)].  
Clinical experience to date is not yet sufficient to substantiate or 
refute this as a safety concern for daprodustat.  • Specific eligibility criteria related to personal 
history of malignancy are outlined in Section  
6.2. 
• Stopping criteria for participants with 
treatment emergent malignancy are outlined 
in Section 8.2.1 . 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
53 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Pulmonary artery hypertension (PAH)  A role for HIF -regulated pathways in the pathophysiology of PAH has 
been suggested based on well -established effects of acute and 
chronic hypoxia in man on the pulmonary vasculature 
(vasoconstriction), and by findings in patients with naturally occurring 
mutations that result in decreased HIF degradation [ Smith , 2006; 
Formenti , 2011].  
There have been no histopathologic findings suggestive of PAH in  
pre-clinical safety studies with daprodustat (up to 13 weeks duration 
in mice and dog, up to 26 weeks in rat, and up to 39 weeks in 
monkeys.  
Acute hypoxic challenge (rats):   Daprodustat produced increases in 
peak right ventricular pressure (PRVP) during a cute hypoxia that 
were slightly higher than the vehicle control group.  These hypoxia -
induced PRVP changes fall within the range of PRVP differences 
noted among non -treated rats.  
Results from a clinical study of acute hypoxic challenge in healthy 
volunteer s demonstrated that short -term (5 days) therapy with 
daprodustat 5 mg or 100 mg has no clinically significant effect on 
echocardiographically -estimated systolic pulmonary artery pressure 
(sPAP) under either normoxic or hypoxic conditions.  
ECHO assessments performed in Phase 2b studies (24 weeks 
treatment duration) did not identify any clinically -meaningful changes 
in sPAP in participants not on dialysis for daprodustat.  In 
hemodialysis participants, mean absolute change from baseline in 
sPAP was similar fo r both treatment groups; however, there was a 
numeric imbalance (Daprodustat: 8 [7%]; Control 0) in participants 
reaching the sPAP PCI (>20 mmHg increase from baseline).  
Regarding this imbalance, there were a number of confounding 
factors in the study, mo st notably a 4.5:1 randomization scheme and 
inconsistency in timing of ECHOs relative to dialysis day.  
Additionally, 2 of 3 participants with resolution of sPAP on safety 
follow -up ECHOs had confounding conditions that could contribute to 
resolution other  than discontinuation of study treatment; and there 
was no dose relationship for participants meeting the sPAP PCI • Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
54 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
criterion.  Overall, there is insufficient evidence to conclude a 
relationship to treatment with daprodustat . A post -hoc analysis was 
perform ed using a definition of PAH commonly cited in the literature 
[Navaneethan , 2016].   Subjects with sPAP >35 mmHg and/or 
tricuspid regurgitation maximum jet  velocity (TRV) >2.5 m/s were 
considered as having PAH.   Regardless of baseline status of PAH, 
there was no clinically meaningful difference in the proportion of 
subjects with on -treatment PAH between the two treatment groups:  
o Subjects with PAH at baseline: 35/113 (31%) vs. 21/54 
(39%) (ND) and 37/115 (32%) vs. 7/21 (33%) (HD), 
daprodustat vs. control, respectively.  
o Subjects without PAH at baseline: 25/113 (22%) vs. 
12/54 (22%) (ND) and 22/115 (19%) vs. 6/21 (29%) 
(HD), daprodustat vs. control, resp ectively.   
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week 
treatment duration)] : Four (0.5%) non -serious AEs in the daprodustat 
group vs 0 in rhEPO.  
• Review of subject level infor mation did not suggest adverse 
treatment effect: 2 subjects from phase2b that met protocol 
specified stopping criteria on scheduled ECHO had non -serious 
AEs of ‘pulmonary arterial pressure increased’ and 2 subjects 
from Japan Phase 3 had non -serious AE ‘pu lmonary 
hypertension’ in setting of concurrent serious AEs of acute 
pulmonary embolus and mitral regurgitation identified during 
hospitalization for coronary angiography . 
Following review of clinical data received to date, this has not been 
identified as a  safety concern for daprodustat.  
Cardiomyopathy  Published data suggest that cardiac effects of HIF stabilization are 
likely a function of the mechanism, extent, and duration of the effects, 
and can range from protective to detrimental depending upon the 
specific model and experimental conditions utilized.  • Monitoring of emerging safety data by an 
internal GSK Safety Review Team  
TMF-13854840  CONFIDENTIAL   
  201771  
55 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Small increases in cardiac troponin in 6 month rat study with 
daprodustat  were consistent with the background finding of 
spontaneo us rodent cardiomyopathy.  There were no elevations 
observed in cardiac troponin in 9 month monkey study with 
daprodustat . 
Cardiomyopathy has not been associated with naturally occurring 
mutation in man which results in increased HIF stabilization.  
ECHO as sessments performed in phase 2b studies (24 weeks 
treatment duration) did not identify any clinically meaningful changes 
in LVEF for daprodustat.  
Integrated AE data from clinical trials with daprodustat [including 2 
global phase 2b studies (24 -week treatment duration) and 2 
Japanese phase 3 studies (52 -week treatment duration)]: No 
meaningful difference was seen between treatment groups in reports 
of this AESI [1 (0.1%) daprodustat vs. 1 (0.2%) rhEPO; 0.64 relative 
risk (95% confidence interval: 0.02 , 18.07)].  
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat.  
Proliferative retinopathy, macular edema, choroidal 
neovascularization  Increases in local (ocular) VEGF production with retinal 
neovascularization and macular edema observed in diabetic 
retinopathy and to choroidal leakage, edema and neovascularization 
seen in age -related macular degeneration [ Campochiaro , 2006].  
Administration of  60 mg/kg daprodustat to mice caused minimal 
increases in circulating VEGF while significant EPO increases were 
observed.  
No ocular abnormalities with daprodustat were seen in non -clinical 
studies of up to 13 weeks duration in mice and dogs, 26 weeks in 
rats, and 39 weeks in monkeys.  
In clinical studies up to 4 weeks duration, a dose -ordered increase in 
VEGF plasma concentrations was observed at doses ranging from 10 • Suspected p roliferative retinopathy, macular 
edema, choroidal neovascularization or  
symptoms consistent with these events 
should be investigated by ophthalmologic 
consult ation as clinically warranted.  
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
56 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
to 150 mg.  In studies up to 24 weeks duration at doses up to 25  mg, 
changes in VEGF plasma concentrations were variable but similar 
relative to control.  
Ophthalmologic assessments performed in phase 2b studies (24 
weeks treatment duration) did not identify a ny clinically meaningful 
changes in proliferative retinopathy, macular edema, or choroidal 
neovascularization  with daprodustat . 
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 studies (52 -week 
treatment duration)] : No meaningful difference was seen between 
treatment groups in reports of this AESI [9 (2.9%) daprodustat vs. 6 
(2.5%) rhEPO; 1.19 relative risk; (95% confidence interval: 0.42, 
3.43)].  
Following review of clinical data with daprodusta t received to date, 
this has not been identified as a safety concern for daprodustat.  
Exacerbation of rheumatoid arthritis  In inflamed rheumatic joints, activation of HIF -related genes 
secondary to decreased oxygen and pro -inflammatory cytokines has 
been postulated to contribute to the neo -angiogenesis, proliferation 
and infiltration of rheumatoid synovial fibroblasts [ Campochiaro , 
2006; Westra , 2010;  Muz, 2009].  
No abnormalities seen in non -clinical studies conducted to date for 
daprodustat.  
Integrated AE data [including 2 global phase 2b studies (24 -week 
treatment duration) and 2 Japanese phase 3 stud ies (52 -week 
treatment duration)]: No meaningful difference was seen between 
treatment groups in reports of this AESI [2 (0.3%) daprodustat vs. 1 
(0.2%) rhEPO; 1.20 relative risk; (95% confidence interval: 0.07, 
20.87) and the incidence of musculoskeletal AEs was generally lower 
in the daprodustat treatment group].  
Following review of clinical data received to date, this has not been 
identified as a safety concern for daprodustat.  • Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
57 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
Drug-drug interactions  Daprodustat is a substrate of CYP2C8 .  Co-administration of 
daprodustat with the strong CYP2C8 inhibitor, gemfibrozil increased 
the Cmax and AUC of daprodustat, 4 - and 19 -fold, respectively, while 
co-administration of the weak inhibitor, trimethoprim increased the 
Cmax and AUC of daprodustat by 1.3 - and 1.5 -fold, respectively.  
Population PK analysis from completed Phase 2 studies suggests 
that co -administration of daprodustat with a moderate CYP2C8 
inhibitor (clopidogrel) leads  to a ~2 -fold increase in AUC, with no 
clinically -significant increase in the measured Hgb response.   
Although CYP2C8 induction  studies were not performed, 
coadministration  of daprodustat with  an inducer of CYP2C8 
(e.g.,rifampin/rifampicin) may decrease  the exposure of daprodustat.  
 • Co-administration of daprodustat  with strong 
CYP2C8 inhibitor s, (e.g., gemfibrozil ) and 
inducers, (e.g., rifampin/rifampicin ) is not 
permitted as outlined in Section  7.7.2 . 
• Specific guidance on the management of 
potential drug -drug interactions and 
concomitant medications is provided in 
Section 7.7. 
• Hgb will be closely monitored throughout the 
dosing period as outlined in the SoA in 
Section 2. 
• Specific guidance for discontinuation of 
daprodustat based on achieved Hgb is 
provided in Section  8.2.1.1 . 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
Cyst progression in patients with autosomal 
dominant polycystic kidney disease (ADPKD)  Published data provide in vivo evidence for a potential role of HIF -1a 
in the growth of polycystic kidneys; Hif -1a deletion was sufficient to 
significantly mitigate a progressive polycystic phenotype in an 
ADPKD mouse model, while conversely pharmacologic HIF-1a 
stabilization was sufficient to convert a mild polycystic disease into a 
severely aggravated phenotype with marked loss of renal function. 
However, the dose of FG -2216 (a PHI) used resulted in a significant 
erythropoietic response as reflected by ≥1 0% relative increases in 
hematocrit over the course of the study.  (Kraus , 2018; Hofherr , 
2018).  
A review of the non -clinical data from toxicity studies conducted with 
daprodustat does not indicate an exacerbation in incidence or 
severity of kidney cysts in daprodustat -treated animals in comparison 
to controls.  However, the wild type animals used in these toxicity • Kidney function  will be monitored throughout 
the dosing period as outlined in the SoA 
(Section 2). 
• Monitoring of emerging safety data by an 
internal GSK Safety Review Team.  
TMF-13854840  CONFIDENTIAL   
  201771  
58 
 Potential Risk of Clinical Significance  Summary of Data/Rationale for Risk  Mitigation Strategy  
studies have a very low background incidence of renal cysts and are 
not comparable to the mice used in the Kraus article ( Kraus , 2018) 
which are an inducible kidney epithelium -specific Pkd1 -deletion 
model . 
There is limited experience w ith daprodustat in subjects with ADPKD 
in completed clinical trials. In the Japan phase 3 study in non -dialysis 
subjects, there were 5 subjects with ADPKD (all CKD stage 5) in 
each treatment group.  Mean baseline eGFR was 10 mL/min/1.73m 2 
in the daprodustat subjects vs. 16 mL/min/1.73m 2 in the rhEPO 
subjects.  The mean (SD) percent change from baseline at Week 52 
in eGFR was: -18% (8) vs. -21% (14) in daprodustat vs. rhEPO, 
respectively.  
Following review of clinical data received to date, this has  not been 
identified as a safety concern for daprodustat.  
TMF-13854840  CONFIDENTIAL   
  201771  
   
59 
 References  
Campochiaro  PA and the first ARVO/Pfizer Institute Working Group et al.  Ocular versus 
extraocular neovascularization: Mirror images or vague resemblances. Invest Ophthalmol 
& Vis Sci.  2006; 47:462 -474. 
Formenti  F, Beer PA, Croft QPP, Dorrington KL, Gale DP, Lappin TRJ, Lucas GS, 
Maher ER, Maxwell PH, McMullin MF, O’Connor DF, Percy MJ, Pugh CW, Ratcliffe 
PJ, Smith TG, Talbot NP, Robbins PA. Cardiopulmonary function in two human 
disorders of the hypoxia -inducible  factor (HIF) pathway: von Hippel -Lindau disease and 
HIF-2α gain -of-function mutation. FASEB J . 2011; 25:2001 -2011.  
Hofherr, A., et al, HIF-1α drives cyst growth in advanced stages of autosomal dominant 
polycystic kidney disease; Kidney International (2018)  94, 849 –851. 
Kraus, A., et al, HIF-1α promotes cyst progression in a mouse model of autosomal 
dominant polycystic kidney disease ; Kidney International, 2018.   
Muz B, Khan MN, Kiriakidis S, Paleolog EM. The role of hypoxia and HIF -dependent 
signallin g events in rheumatoid arthritis. Arthritis Research & Therapy  2009; 11:201 -
209. 
Navaneethan SD, for CRIC investigators: Prevalence, Predictors, and Outcomes of 
Pulmonary Hypertension in CKD. J Am Soc Nephrol  2016, 27:877 –886. 
Smith TG, Brooks JT, Balanos GM, Lappin TR, Layton DM, Leedham DL, Liu C, 
Maxwell PH, Treacy M, Robbins PA. Mutations of von Hippel -Lindau tumour 
suppressor and heman cardiopulmonary physiology. PLos Med.  2006; 3:3290.  
Westra J, Molema G, Kallenberg CG. Hypoxia -inducible factor -1 as r egulator of 
angiogenesis in rheumatoid arthritis - therapeutic implications. Curr Med Chem.  2010; 
17:254 -63. 
TMF-13854840  CONFIDENTIAL   
  201771  
60 
 12.4.  Appendix 4: Clinical  Laboratory Assessment s 
The tests detailed in Table 8 will be performed by a central labo ratory.  
 
 
• Local laboratory results are only required in the event that the central laboratory 
results are not available in time for either study treatment administration and/or 
response evaluation.   If a local sample is required, it is important that the sample 
for central analysis is obtained at the same time.   Additionally, if the local 
laboratory results are used to make ei ther a study treatment decision or response 
evaluation, the results must be e ntered into the eCRF.  
• Protocol -specific requirements for inclusion or exclusion of participants are 
detailed in Section 6 of the protocol.  
• Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations.  
 
Table 8 Clinical Laboratory Assessments  
Assessments  Parameters  
Hematology  Platelet Count  
RBC Count  
Hgb 
Hematocrit  RBC Indices:  
MCV  
MCH  
%Reticulocytes  WBC count with Differential : 
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  
Clinical 
Chemistry1 BUN  Potassium  Aspartate 
Aminotransferase  
(AST)/ Serum 
Glutamic -
Oxaloacetic 
Transaminase 
(SGOT)  Total and direct 
bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase  
 (ALT)/ Serum 
Glutamic -Pyruvic 
Transaminase 
(SGPT)  Total Protein  
 Glucose  Calcium  Alkaline 
phosphatase   
Routine 
Urinalysis  • Specific gravity  
• pH, glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, 
leukocyte esterase by dipstick  
• Microscopic examination (if blood or protein is abnormal)  
TMF-13854840  CONFIDENTIAL   
  201771  
61 
 Assessments  Parameters  
Other 
Laboratory 
Analyses  • Follicle -stimulating hormone and estradiol (as needed in women of non -
childbearing potential only)  
• Urine human chorionic gonadotropin (hCG) pregnancy test (as needed 
for women of childbearing potential)2 
• HIV antibody  
• Folate , high sensitivity C -reactive protein, Vitamin B 12 
• Serum iron,  ferritin, transferrin, transferrin saturation, soluble transferrin 
receptor, hepcidin, erythroferrone  
• Hemoglobin, hematocrit, red blood cell number, mean corpuscular 
volume, reticulocyte hemoglobin, reticulocyte number  
1 Details of liver chemistry stopping criteria and required actions and follow -up assessments after liver 
stopping or monitoring event are given in Section 8.1.1  and Appendix  2.  All events of ALT 3 × upper 
limit of normal (ULN) and bilirubin  2 × ULN (> 35% direct bilirubin) or ALT 3 × ULN and 
intern ational normalized ratio (INR) > 1.5, if INR measured, which may indicate severe liver injury 
(possible Hy’s Law), must be reported as an SAE (excluding studies of hepatic impairment or cirrhosis).  
2 Local urine testing will be standard for the protocol unless serum testing is required by local regulation 
or IRB/IEC.  
 
TMF-13854840  CONFIDENTIAL   
  201771  
62 
 12.5.  Appendix 5: Study Governance Considerations  
Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with:  
• Consensus ethical principles derived  from international guidelines 
including the Declaration of Helsinki and Council for International 
Organizations of Medical Sciences (CIOMS) International Ethical 
Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulat ions 
• The protocol, protocol amendments, ICF, Investigator Brochure, and other 
relevant documents (e .g., advertisements) must be submitted to an IRB/IEC by 
the investigator and reviewed and approved by the IRB/IEC before the study is 
initiated.  
• Any amendme nts to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.  
• The investigator will be responsible for the following:  
• Provi ding written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/EC  
• Notifying the IRB/IEC of SAE or other significant safety findings as 
requir ed by IRB/IEC procedures  
• Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local reg ulations  
Financial Disclosure  
Investigators and sub -investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to  the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.  
Informed Consent Process  
• The investigator or his/her repres entative will explain the nature of the study to 
the participant or his/her legally authorized representative and answer all 
questions regarding the study.  
• Participants must be informed that their participation is voluntary. Participants 
or their legally authorized representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
TMF-13854840  CONFIDENTIAL   
  201771  
63 
 ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) 
requirements, where applicable, a nd the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorized person obtaining the informed  consent 
must also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) 
during their participation in the study.  
• A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorized represen tative.  
• Participants who are rescreened are required to sign a new ICF.  
The ICF may contain a separate section that addresses the use of remaining mandatory 
samples for optional exploratory research in accordance with SOP -GSKF -410.  The 
investigator or au thorized designee will explain to each participant the objectives of the 
exploratory research.   Participants will be told that they are free to refuse to participate 
and may withdraw their consent at any time and for any reason during the storage period.  
A separate signature will be required to document a participant's agreement to allow any 
remaining specimens to be used for exploratory research.  Participants who decline to 
participate will not p rovide this separate signature.  
Data Protection  
• Participant s will be assigned a unique identifier by the sponsor. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred.  
• The participant must be informed that his/her personal study -related data will be 
used by the sponsor in accordance with local data protection law. The level of 
disclosure must also be explained to the participant.  
• The participant must be in formed that his/her medical records may be examined 
by Clinical Quality Assurance auditors or other authorized personnel appointed 
by the sponsor, by appropriate IRB/IEC members, and by inspectors from 
regulatory authorities.  
Publication Policy  
• The results  of this study may be published or presented at scientific meetings.  If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission.  This allows the sponsor to protect proprietary 
information and to p rovide comments.  
• The sponsor will comply with the requirements for publication of study results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generally support publication of multicenter studies only in their entirety and no t 
as individual site data.  In this case, a coordinating investigator will be 
designated by mutual agreement.  
TMF-13854840  CONFIDENTIAL   
  201771  
64 
 • Authorship will be determined by mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements.  
Dissemination of Clinical Study Data  
• Where required by applicable regulatory requirements, an investigator signatory 
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results at a 
GSK site or other mutually -agreeable location.  
• GSK will also provide the investigator with the full summary of the study results.  
The investigator is enc ouraged to share the summary results with the study 
subjects, as appropriate.  
• The procedures and timing for public disclosure of the results summary and for 
development of a manuscript for publication will be in accordance with GSK 
Policy.  
Data Quality Ass urance  
• All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically (e .g., 
laboratory data).  The investigator is responsible for verifying that data entries 
are accur ate and correct by physically or electronically signing the CRF.  
• The investigator must maintain accurate documentation (source data) that 
supports the information entered in the eCRF.  
• The investigator must permit study -related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents.  
• The sponsor or designee is responsible for the data management of this study 
includin g qua lity checking of the data.  
• Study monitors will perform ongoing source data verification to confirm that 
data entered into the eCRF by authorized site personnel are accurate, complete, 
and verifiable from source documents; that the safety and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements.  
• Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by the investigator for 15 years after study completion 
unless local regulat ions or institutional policies require a longer retention period.  
No records may be destroyed during the retention period without the written 
approval of the sponsor.  No records may be transferred to another location or 
party without written notification  to the sponsor.  
TMF-13854840  CONFIDENTIAL   
  201771  
65 
 Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.  
• Data reported on the CRF or entered in th e eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained.   The investigator may need to request previous 
medical records or transfer records, depending on the study.  Also, curren t 
medical records must be available.  
• Definition of what constitutes source data can be found in the SRM.  
Study and Site Closure  
GSK or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole dis cretion of GSK. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study -site closure visit has been performed.  
The investigator may initiate study -site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the sponsor or investigator may include 
but are not limited to:  
• Failure of th e investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines  
• Inadequate recruitment of participants by  the investigator  
• Discontinuation of further study treatment devel opment  
TMF-13854840  CONFIDENTIAL   
  201771  
66 
 12.6.  Appendix 6: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting  
Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study  intervention , whether or not considered related to the 
study intervention . 
• NOTE: An AE can therefore be any unfavorable and unintended s ign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention . 
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments (e .g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the medical 
and scientific judgment of the investigator (ie, not related to progression of underlying 
disease).  
• Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study intervention  administratio n even though 
it may have been present before the start of the study.  
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definitio n  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.  
• The diseas e/disorder being studied or expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participant’s 
condition.  
• Medical or surgical procedure (e .g., endoscopy, appendectomy): the condition that leads 
to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).  
TMF-13854840  CONFIDENTIAL   
  201771  
67 
 • Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen.  
Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e .g., hospitalization for signs/symptoms of the disease under study, 
death due to prog ression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
b. Is life -threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event.   It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
In general, hospitalization signifies that the p articipant has been detained (usually involving at 
least an overnight stay) at the hospital or emergency ward for observation and/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting.  Complications 
that occur d uring hospitalization are AE.  If a complication prolongs hospitali zation or fulfil s 
any other serious criteria, the event is serious.  When in doubt as to whether “hospitalization” 
occurred or was necessary, the AE should be considered serious.  
Hospitaliz ation for elective treatment of a pre -existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal 
life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and 
accidental trauma (e .g., sprained ankle) which may interfere with or prev ent everyday life 
functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Other situations:  
• Medical or scientific judgment should be exercised in deciding whether SAE reporting is 
appropriate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospitalization but may jeopardize t he 
participant or may require medical or surgical intervention to prevent one of the other 
outcomes listed in the above definition.  These events should usually be considered 
serious.  
Examples of such events include invasive or malignant cancers, intensive  treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions 
that do not result in hospitalization, or development of drug dependency or drug abuse.  
 
TMF-13854840  CONFIDENTIAL   
  201771  
68 
 Definition of Cardiovascular Events  
Cardiovascular Events (CV) D efinition:  
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:  
• Myocardial infarction/unstable angina  
• Congestive heart failure  
• Arrhythmias  
• Valvulopathy  
• Pulmonary hypertension  
• Cerebrovascular events/stroke and transient ischemic attack  
• Peripheral arterial thromboembolism  
• Deep venous thrombosis/pulmonary embolism  
• Revascularization  
 
Recording AE and SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e .g., hospital progress notes, laboratory, and diagnostics reports) related 
to the event.  
• The investigator will then record all relevant AE/SAE information in the eCRF.  
• It is not acceptable for the investigator to send photocopies  of the participant’s medical 
records to GSK  in lieu of completion of the GSK /AE/SAE eCRF page.  
• There may be instances when copies of medical records for certain cases are requested by 
GSK .  In this case, all participant identifiers, with the exception of the participant number, 
will be redacted on the copies of the medical records before submission to GSK . 
• The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information.  Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensit y 
The investigator will make an assessment of intensity for each AE and SAE reported during the 
study and assign it to  1 of the following categories:  
• Mild: An event that is easily tolerated by the participant, causing minimal discomfort and 
not interferin g with everyday activities.  
• Moderate: An event that causes sufficient discomfort and interferes with normal everyday 
activities.  
TMF-13854840  CONFIDENTIAL   
  201771  
69 
 • Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE.   Severe is a category utilized for rating the 
intensity of an event; and both AE and SAE can be assessed as severe.  
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.  
 
Assessment of Causality  
• The investigator is obligated to assess the relationship between study treatment and each 
occurrence of each AE/SAE.  
• A "reasonable possibility" of a relationship conveys that there are facts, evidence, and/or 
arguments to suggest a causal relationship, rather than a relationship cannot be ruled out.  
• The investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention  
administration will be considered and investigated.  
• The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.  
• For each AE/SAE, the investigator must  document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causality.  
• There may be situations in which an SAE has occurred,  and the investigator has minimal  
information to include in the initial report to GSK .  However, it is very important that 
the investigator always make an assessment of causality for every event before the 
initial transmission of the SAE data to GSK . 
• The investigator may change his/her opinion of causality in light of follow -up information 
and send an SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting 
requirements.  
Follow -up of AE and SAE  
• The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK to 
elucidate the nature and/or causality of the AE or SAE as fully as possible.  This may 
include additional laboratory tests or investigations, histopathological examinations, or 
consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow -up 
period, the investigator wil l provide GSK with a copy of any post -mortem fin dings 
including histopathology.  
• New or updated information will be recorded in the originally completed eCRF.  
• The investigator will submit any updated SAE data to  GSK within 24 hours of receipt of 
the information.  
 
TMF-13854840  CONFIDENTIAL   
  201771  
70 
 Reporting of SAE to GSK  
SAE Reporting to GSK  via Electronic Data Collection Tool  
• The primary mechanism for reporting SAE to GSK will be the electronic data collection 
tool. 
• If the electronic system is unavailable, then the site will use the  paper SAE data collection 
tool (see next section)  in order to report the event within 24 hours . 
• The site will enter the SAE data into the electronic system as soon as it becomes available.  
• The investigator or medically -qualified sub -investigator must show  evidence within the 
eCRF (e.g., check review box, signature, etc.) of review and verification of the 
relationship of each SAE to IP/study participation (causality) within 72 hours of SAE 
entry into the eCRF.  
• After the study is completed at a given site, t he electronic data collection tool will be 
taken off -line to prevent the entry of new data or changes to existing data.  
• If a site receives a report of a new SAE from a study participant or receives updated data 
on a previously reported SAE after the electr onic data collection tool has been taken off -
line, then the site can report this information on a paper SAE form (see next section) or to 
the Medical Monitor  by telephone.  
• Contacts for SAE reporting can be found in the SRM . 
 
SAE Reporting to GSK via Paper  CRF  
• Facsimile transmission of the SAE paper CRF is the preferred method to transmit this 
information to the Medical Monitor.  
• In rare circumstances and in the absence of facsimile equipment, notification by telephone 
is acceptable with a copy of the SAE data collection tool sent by overnight mail or courier 
service.  
• Initial notification via telephone does not replace the need for the investigator to complete 
and sign the SAE CRF pages within the designated reporting time frames.  
• Contacts for SAE reporting  can be found in SRM.  
 
TMF-13854840  CONFIDENTIAL   
  201771  
71 
 12.7.  Appendix  7: Contraceptive Guidance and Collection of 
Pregnancy Information  
Definitions  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanently sterile (see below)  
Women in the following categories are not considered WOCBP  
1. Premenarchal  
2. Premenopausal female with ONE of the following:  
• Documented hysterectomy  
• Documented bilateral salpingectomy  
• Documented bilateral oophorectomy  
Note:  Documentation ca n come from the site personnel’s  review of participant’s 
medical records, medical examination, or medical history interview.  
3. Postmenopausal female  
• A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause.  A high fo llicle stimulating hormone (FSH) level in 
the postmenopausal range may be used to confirm a postmenopausal state in 
women not using hormonal contraception or hormonal replacement therapy 
(HRT).  However, in the absence of 12 months of amenorrhea, a single FSH 
measurement is insufficient.  
• Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non -hormonal highly effective contraception methods if they wish 
to continue their HRT during the study.  Otherwise, they must discon tinue HRT 
to allow confirmation of postmenop ausal status before study enrol ment.  
Contraception Guidance  
Female participants  
Female participants of childbearing potential are eligible to participate if they agree to 
use a highly effective method of contraception consistently and correctly as described in  
Table 9. 
 
 
 
 
TMF-13854840  CONFIDENTIAL   
  201771  
72 
 Table 9 Highly Effective Contraceptive Methods  
Highly Effective Contraceptive Methods That Are User Dependent1 
Failure rate of <1% per year when used consistently and correctly.  
Combined (estro gen- and progestogen -containing ) hormonal contraception associated with 
inhibition of ovulation2 
• oral 
• intravaginal  
• transdermal  
Progestogen -only hormonal contraception associated with inhibition of ovulation2 
• injectable  
Highly Effective Methods That Are User Independent  
• Implantable progestogen -only hormonal contraception associated with inhibition of 
ovulation2 
• Intrauterine device (IUD)  
• Intrauterine hormone -releasing system (IUS)  
• bilateral tubal occlusion  
Vasectomized partner  
(A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. )  
Sexual abstinence  
(Sexual abstinence is considered a highly effective method only if defined as refraining from 
heterosexual intercourse during the entire period of risk associated with the study drug. The 
reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.)  
1 Typical use failu re rates may differ from those when used consistently and correctly.   Use should be consistent with 
local regulations regarding the use of contraceptive methods for participants in clinical studies.  
2 Hormonal contraception may be susceptible to interactio n with the study drug, which may reduce the efficacy of the 
contraceptive method.   In this case two highly effective methods of contraception should be utilized during the 
treatment period and at least to the follow -up visit.  
 
Pregnancy Testing  
• WOCBP should only be included after a confirmed menstrual period and a negative 
highly sensitive urine  pregnancy test . 
• Pregnancy testing will be performed whenever a menstrual cycle is missed or when 
pregnancy is otherwise suspected . 
• Pregnancy testing, wit h a sensitivity of 25 mIU/mL will be performed using the test 
kit provided by the central laboratory and in accordance with instructions p rovided in 
its package insert.  
TMF-13854840  CONFIDENTIAL   
  201771  
73 
 Collection of Pregnancy Information  
Female Participants who become pregnant  
• Investigato r will collect pregnancy information on any female participant, who 
becomes pregnant whi le participating in this study.  
• Information will be recorded on the appropriate form and submitted to GSK within 
24 hours of learnin g of a participant's pregnancy.  
• Participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK .  Generally, follow -up will not be required for longer than 6 to 
8 weeks beyon d the estimated delivery date.  
• Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalie s) or indication for procedure.  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complic ation or elective termination of a pregnancy wi ll be reported as an AE or 
SAE.  
• A spontaneous abortion is always considered to be an SAE  and will be reported as 
such.  
• Any SAE occurring as a result of a post -study pregnancy which is considered 
reasonably rel ated to the study treatment by the investigator, will be reported to GSK 
as described in Appendix 6.  While the investigator is not obligated to actively se ek 
this information in former study participants, he or she may learn of an SAE  through 
spontaneous reporting.  
Any female participant who become s pregnant while participating will discontinue study 
treatment and be withdrawn from the study . 
TMF-13854840  CONFIDENTIAL   
  201771  
74 
 12.8.  Appendix  8: Genetics  
USE/ANALYSIS OF DNA  
• Genetic variation may impact a participant’s response to therapy, susceptibility, 
severity and progression of disease.  Variable response to therapy may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and 
excretion; mechanism of action of the drug; disease etiology; and/or molecular 
subtype of the disease being treated.  Therefore, wher e local regulations and 
IRB/IEC allow, a blood  sample will be collected for DNA analysis . 
• DNA samples will be used for research related to daprodustat  or anemia of chronic 
kidney disease  and related diseases.  They may also be used to develop tests/assays 
(including diagnostic tests) related to daprodustat or anemia of chronic kidney 
disease .  Genetic research may consist of the analysis of one or more candidate genes 
or the analysis of genetic markers throughout the genome [or analysis of the entire 
genome ] (as appropriate) . 
• DNA samples will be analyzed if it is hypothesized that this may help further 
understand the clinical data . 
• The samples may be analyzed as part of a multi -study assessment of genetic factors 
involved in the response to daprodustat  or study treatments of this class.  The results 
of genetic analyses may be reported in the clinical study report or in a separate study 
summary.  
• The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.  
• The samples will be retained while research on daprodustat  (or study treatments of 
this class) or anemia of chronic kidney disease  continues but no longer than 15 years 
or other period as per local requirements.  
 
TMF-13854840  CONFIDENTIAL   
  201771  
75 
 12.9.  Appendix 9: Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents (TOC).  
Previous Amendment:  
Amendment 2 13 -Aug-2019  
Overall Rationale for the Amendment :  
After the publication of the first protocol amendment,  the iron for ingestion needed to be 
compounded differently.  
In order to ensure tighter control of iron supplementation given the purpose of this study, 
specific parameters for iron supplementation were provided.  Similarly, a revision was 
made t o include additional weight measurements of participants in case of significant 
unexpected weight loss or gain during the study.  This could have bearing on blood 
volume and ultimately iron content within an individual.  
 
Exclusion criterion #18 was revise d to exclude all individuals with hypertension deemed 
“uncontrolled” per the discretion of the primary investigator instead of specific blood 
pressure parameters in order to align with the daprodustat program.  
 
Discrepancies were noted between Section 9.2. 8 and the pregnancy guidance in 
Appendix 7; these respective sections were updated accordingly.  
 
Revisions were made throughout the protocol to align with GSK standard language and 
for clarity where necessary.  More specific rationales are provided for each item in this 
category in the table below.  
 
Section # and 
Name  Description of Change  Brief Rationale  
Short title and 
1 Synopsis  The short title was changed.  All studies for this asset have a similar 
nomenclature; this change is to align globally.  
1 and 4 
Objectives and 
Endpoints  Safety endpoints were moved into 
their own section. No additions or 
deletions in the endpoint text.  To permit easier identification of safety 
endpoints.   
2 Schedule of 
Activities  A weight assessment was added to 
several visits throughout the study 
period.  To allow more accurate calculations of the 
fractional iron absorption should a participant 
experience a significant weight change during 
the study.  
6.1 Inclusion 
Criteria  Criterion 5 was updated to provide 
parameters for consistent provision of 
iron supplementation.  For clarity.  
6.2 Exclusion 
Criteria  Updated the language in the 
exclusion criterion #18 surrounding 
blood pressure.  To align with the daprodustat program .  
TMF-13854840  CONFIDENTIAL   
  201771  
76 
 Section # and 
Name  Description of Change  Brief Rationale  
7.1 Treatments 
Administered  The revised  formulation of the iron 
isotope solution was provided . To reflect the contents of the revised iron 
isotope solution.   
7.1.3 57Fe 
Dosing 
Information  The description and formulation of 
the iron isotope (57Fe) was updated.  To reflect the  revised procedure  for provision 
of the 57Fe isotope  used in the study.  
7.1.4 58Fe 
Dosing 
Information  The description, dosing, and 
formulation of the iron isotope (58Fe) 
was updated.  To reflect the revised procedure  for provision 
of the 58Fe isotope  used in the study.  
7.7.2 
Prohibited 
Medications  High dose clopidogrel (300 mg) was 
added.  An additional example of a strong CYP2C8 
inhibitor was added.  
8.2.1.1 Hgb 
Stopping 
Criteria  The structure of Table 2 was 
modifie d. For clear distinction between assessment of 
the Hgb and resultant action(s).  
9.2 Adverse 
Events  Updated GSK standard language.  For consistency among GSK protocols.  
9.2.8 
Pregnancy  Text was updated to reflect guidance 
given in Appendix 5.  Correction  of error . 
10.3.2 Interim 
Analysis  The potential for an interim analysis 
was removed.  GSK deemed the interim analysis was no 
longer necessary in support of the 
daprodustat program.  
12.3 Appendix 
3: Risk 
Assessment  Several updates were made to the 
risk assessment table.  The benefit -risk table was recently updated.  
12.6 Appendix 
6: Definition of 
Cardiovascular 
Events  The table with definitions of 
cardiovascular events was added.  For consistency among GSK protocols.  
12.6 Appendix 
6: Reporting of 
SAE to GSK  Additional text surrounding the 
requirement for the PI to review SAEs 
and to provide causality within 72 
hours of the SAE entry into the eCRF 
was added.  For consistency among GSK protocols.  
 
Amendment 1 30 -Nov-2017  
Overall Rationale for the Amendment:  It was noted that one exclusion criterion was 
incorrect. This amendment serves to revise that as well as streamline the study 
procedures, as noted from investigators.  Lastly, minor spelling and context errors were 
corrected.  
TMF-13854840  CONFIDENTIAL   
  201771  
77 
 Section # 
and Name  Description of Change  Brief Rationale  
6.2 Exclusion 
Criteria  Changed criterion to high 
sensitivity CRP; Corrected value 
for hsCRP exclusionary criterion  To have clear exclusion criteria; ensure 
consistency with other program protocols  
6.2 Exclusion 
Criteria  Changed the prior clinical study 
experience criteria from 120 days 
to 30 days  Ensure consistency with other program 
protocols; re -evaluation determined this 
duration is not necessary; improve 
recruitment.  
2 Schedule of 
Assessments  Updated pregnan cy testing time 
points.   More complete pregnancy testing 
throughout the study; better compliance 
with GSK standards.  
2 Schedule of 
Assessments  Changed routine urinalysis to 
coincide with urine pregnancy 
testing.  Ease of procedural parameters for the 
sites.  
2 Schedule of 
Assessments  Added in one time point for 
isotopic iron blood sampling  Affords more robust analysis of absorption 
of one isotope vs the other  
2 Schedule of 
Assessments  Added/changed various time 
points for vital signs  More complete mon itoring throughout 
study; better compliance with GSK 
standards.  
2 Schedule of 
Assessments; 
Appendix 4  Ferritin included in a footnote for 
the iron status markers and added 
to the Laboratory Assessments 
Table  Initial intention was to include ferritin in the 
iron status markers.  Adds consistency 
throughout the document as ferritin is 
listed in the Objectives and Endpoints as 
well as the Iron Status Markers Section 
(9.8.2)  
Appendix 4  Clinical Laboratory Assessments 
Table 8 and Table 9  were 
combined  The tw o tables were combined for a more 
clear understanding of the laboratory 
assessments for the study.  
Section 9.4.1  Table 4 was updated to reflect the 
changes in the Schedule of 
Assessments.  For consistency.  
2 Schedule of 
Assessments, 
Section 9.8.2  Iron s tatus markers collection  Additional guidance given for blood draw 
relative to IP dosing  
Section 12.4, 
Table 8  Fasting Glucose  Removed the fasting requirement for this 
lab value; determined to be unnecessary 
for this study.  
 